Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-1-
GENERATING, VIEWING, INTERPRETING, AND UTILIZING
A QUANTITATIVE DATABASE OF METABOLITES
FIELD
This disclosure relates to ways of quantifying metabolites and collecting
quantitative data on
metabolites, a database of quantified metabolite profiles, and methods of
mining and visualizing
selected subsets thereof.
BACKGROUND
The recent explosion of data acquisition and analysis technology, termed
informatics,
promises to revolutionize predictive and diagnostic medicine. The information
readily available to
doctors and scientists today dwarfs that of even a few years ago, and will
expand at an even more
accelerated rate in the next few years. Managing this information and applying
it to useful purpose
are formidable challenges.
Currently, genomics is the most developed and recognized form of biological
informatics.
Genomics developed to simultaneously identify the elements of heredity and to
assign biological
function to these elements. Despite the inherent complexity of the genome, the
invention of just a
few molecular tools enabled genomics to flourish into the science known today.
In the near future, it
is likely that most common genetic diseases will have been identified, many
using genomic tools.
The power of the knowledge emerging from the genome is that identifying the
genetic basis of an
inherited disease can provide logical strategies to treat those afflicted on
an individual basis.
However, genomics is not a panacea for predictive medicine because phenotype
is not necessarily
predicted by genotype. Beyond its application to diseases with demonstrably
genetic causes,
however, the direct utility of genomics by itself diminishes.
Ultimately, changes in phenotype and not changes in genes (genotype) are of
direct interest
to nutrition and health. The gap between genotype and phenotype is spanned by
many biochemical
steps, each with individual specificities and a sensitivity to various
influences, including diet and the
environment. In the chain of biomolecules from genes to phenotype, metabolites
are the quantifiable
molecules with the closest link to phenotype. Many phenotypic and genotypic
states are
characterized or predicted by differences in the concentration of metabolites
within biological tissues
or fluids. For example, the progression of coronary artery disease can be
predicted by the serum
concentration of cholesterol and the presence of non-insulin dependant
diabetes is characterized by
elevated plasma free fatty acids.
Metabolite informatics, or metabolomics, represents a more logical approach
than genomics
for identifying trends or metabolic profiles of specific diseases. While the
assessment of disease in
man has been pursued using individual metabolite assessments, there are no
technologies that enable
the accumulation of diverse metabolome data in a single seamless and
expandable resource. Such a
resource would allow global metabolic effects of disparate affectors to be
compared and contrasted.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-2-
Data for such a resource would need to be quantitative so that data from many
investigators,
analytical technologies, and sample matrices could be integrated and compared.
A quantitative
database of metabolites containing samples from systems treated with many
affectors or expressing
many phenotypic or genotypic traits could be used to identify the molecular
mechanisms consistent
and divergent across many biological systems and individual samples and sample
collections.
Early attempts to use a metabolomic strategy for investigating phenotype have
proven
valuable across a broad spectrum of biological research. In microbiology,
changes in metabolite
profiles were used to describe the global metabolic response and variable
glucose metabolism of E.
coli under different growth conditions (Tweeddale et al., J. Bacteriology
180:5109-5116, 1998).
Metabolome analyses were also used to identify the global changes in E. coli.
metabolism caused by
changes in population density (Liu et al., J. Bacteriology 182:4158-4164,
2000). Raamsdonk et al.
(Nature Biotechnology 19:45-50, 2001) used metabolomic analyses of yeast to
identify the metabolic
function of deleted genes for which there was no observable phenotypic
consequence of their
deletion. Using metabolomics to identify the function of genes demonstrates
the versatility and
power of metabolomics. Unlike genomics and proteomics, metabolomics can be
used to identify
y changes that occur at all levels of biology from genes to environment. The
direct results of
nutritional, genomic or expression differences can be observed in a metabolite
profile. This strategy
is also widely accepted in plant research as a method for screening for
desirable traits, and for
understanding the phenotypic expression of genes (Fiehn et al., Nature
Bioteclzzzology 18:1157-1161,
2000; Glassbrook et al., Nature Bioteclzzzology 18:1157-1161, 2000).
What is needed is a system for creating a quantitative bioinformatic database
of metabolites,
such as lipid metabolites, suitable for integrative research and valid
comparative studies across many
disciplines and sample systems. Further, there is a need to develop easy,
understandable tools for
mining, visualizing and interpreting this bioinformatic resource. Technologies
are needed that can
create and interact with accessible annotated databases of metabolite
concentrations reflective of
individuals in various phenotypic states.
SUMMARY OF THE DISCLOSURE
This disclosure provides methods for generating and storing quantitative
metabolome data,
particularly lipid metabolome data, in a way that is infinitely expandable and
thus suitable for
creating a quantitative database of metabolites. Further, this disclosure
provides methods for mining
this database with visual tools, including computer-mediated user interfaces,
to discover relations
among metabolites from different subsets of the database.
Particular examples provided herein relate to methods of generating,
assembling, organizing,
mining, analyzing, and displaying lipid metabolomic (lipomic) data.
The power and accuracy of predictive diagnostics stand to improve dramatically
as a result
of lipid metabolomics. The high definition of data obtained with this approach
allows multiple rather
than single metabolites to be used in markers for a group. Because as many as
forty fatty acids are
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-3-
quantified from each lipid class, and up to fifteen lipid classes can be
quantified easily, more than six
hundred individual lipid metabolites can be measured routinely for each
sample. Because these
analyses are comprehensive, only the most appropriate and unique metabolites
are selected for their
predictive value. Thus, comprehensive lipid analysis promises to greatly
improve predictive
diagnostics for phenotypes that directly or peripherally involve lipids.
Also provided herein are databases and computer systems for storing,
accumulating, sorting,
selecting, and analyzing metabolomic data.
Further provided embodiments are internal standards and internal standard
compositions,
particularly internal standards and internal standard compositions useful for
analysis of lipids in
biological samples.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a schematic overview of metabolomic analysis as provided herein.
Quantitative
analysis is used to measure a plurality of metabolites from a sample; the raw
data produced by such
analysis is optionally subjected to one or more transformations (e.g.,
computer calculations),
including for instance integration of the area under a chromatogram curve with
or without correction.
Raw data and/or transformed data are entered into a database of results. In
certain of the provided
embodiments, a quality control mechanism compares the entered data against
existing data in the
database and identifies aberrant or erroneous data, which may lead to re-
testing or repeated analysis.
The database can be queried, for instance using filters or other
discrimination mechanisms, and
subsets of data that fit the query displayed. Such displays may be in any
format, for instance in
statistical or graphical formats as provided herein.
Figure 2 is a schematic representation of certain lipid metabolite analysis
embodiments.
Chromatographic data is entered into a database, which can be mined for
desired information and
presented in the form of a graphical interface (for instance a heat map or
targeting chart, as shown in
the second panel). Such interfaces may be optionally provided in interactive
form on a computer
system, or remotely across, for instance, the Internet or another computer
communication system.
Data mined from the cumulative lipid metabolite database can be used, for
instance, for clinical or
diagnostic testing (e.g., for a propensity to obesity), or to identify
specific metabolic targets of drugs,
as described in more detail herein.
Figure 3 is a diagram showing an overview of the pathways of de novo fatty
acid
metabolism in humans.
Figure 4 is a set of chromatograms of the indicated samples, produced by gas
chromatography. FIG 4A shows the gas chromatogram of a sample of Menhaden oil.
FIG 4B shows
a mirrored chromatogram, in which the Menhaden oil chromatogram is displayed
top to bottom with
a control chromatogram that contains standard compounds for comparison
(labeled "Standard
Sample"). Major peaks are identified as indicated.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-4-
Figure 5 is a representative "heat map" display of lipomic data, illustrating
effects of
rosiglitazone treatment on individual lipid metabolites. The concentration
(expressed in nmol/g
sample) of each lipid metabolite from treated and untreated mice was used to
generate a heat map.
The tissue and lipid class of each sample is indicated in the row headers
(left). The fatty acid or
sterol is indicated in the column headers (top). Color coding indicates the
percentage difference
between a control sample and the test sample, as explained below and in
Example 1. The column
headers represent an individual fatty acid present in the lipid classes, which
are displayed on the left.
The magnitude of the difference, expressed as a percentage change in the
quantitative data between
treated and untreated mice, is represented by color according to the legend.
Differences not meeting
a P < 0.05 are displayed in black.
Summary data is presented in the smaller chart to the right, and includes nM
of each fatty
acid for each tissue: (1) total fatty acids, (2) saturated fatty acids, (3)
mono-unsaturated fatty acids,
(4) poly-unsaturated fatty acids, (5) n3, (6) n6, (7) n7, (8) n9 unsaturated
fatty acids, and (9)
plasmalogens ("dm").
Figure 5' is a duplicate of Figure 5, but is printed in grey-tones rather than
in color.
Figure 6 is a representative "targeting chart" display of lipomic data. This
chart shows the
different degrees of lipid metabolite changes when an animal is treated with
CL316,243, a [3-3
adenergenic agonist versus rosiglitazone, a thiazolidinedione.
Figure 6' is a duplicate of Figure 6, but is printed in grey-tones rather than
in color.
Figure 7 shows an example of a heat map indicating that rosiglitazone
treatment exerts
strong and tissue-specific effects on lipid class metabolism. The
concentration (expressed in nmol/g
sample) of each lipid metabolite from treated and untreated mice was used to
generate the summary
data displayed here as a heat map. The first column displays the quantitative
difference in the
concentration of each lipid class between the groups. The next columns, in
order, describe the
quantitative difference in the concentration of saturated fatty acids,
monounsaturated fatty acids,
polyunsaturated fatty acids, n3 fatty acids, n6 fatty acids, n7 fatty acids,
n9 fatty acids, and
plasmalogen lipids among the groups. The magnitude of the difference,
expressed as a percentage
change in the quantitative data between treated and untreated mice, is
represented by color.
Figure 7' is a duplicate of Figure 7, but is printed in grey-tones rather than
in color.
DETAILED DESCRIPTION
L Abbreviatioras
CDP-DAG: CDP-diacylglycerol
CE: cholesterol
ester
CL: cardiolipin
DAG: diacylglycerides
FAME: fatty acid methyl
ester
FFA: free fatty acid
LMP: lipid metabolite
profile
LY: lyso-phosphatidylcholine
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-5-
LyCL: lysocardiolipin
LyPE: lysophosphatidylethanolamine
MAG: monoacylglycerides
PA: phosphatidic acid
PC: phosphotidylcholine
PE: phosphatidylethanolamine
PG: phosphatidylglycerol
PI: phosphotidylinositol
PS: phosphotidylserine
~ PS/I: phosphotidylinositol l phosphotidylserine
SP: sphingomyelin
TAG: triacylglycerol
IZ Explanation of Certain Terms
Unless otherwise noted, technical terms are used according to conventional
usage.
Definitions of common terms in molecular biology may be found in Benjamin
Lewin, Gerzes V,
published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et
al. (eds.), The
Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994
(ISBN 0-632-02182-
9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a
Conzprelzensive Desk
Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
In order to facilitate review of the various embodiments, the following
explanations of
certain terms are provided:
Biological Sample: Any biological material, such as a cell, a collection of
cells (e.g.,
cultured cells), a tissue sample, a biopsy, or an organism. Biological samples
also include blood and
blood products (e.g., plasma) and other biological fluids (e.g., tears, sweat,
saliva and related fluids,
urine, tears, mucous, and so forth). Tissue samples can be from any organ or
tissue in the body,
include heart, liver, muscle, adipose, brain, lung, testes, and brain.
Biological samples may be from individual subjects (e.g., animals, such as
humans, mice,
rats, monkeys, chiekens, cats, dogs, pigs, horses, cows, fruit flies, or
worms) and/or archival
repositories. The samples may be acquired directly from the individuals, from
clinicians (for
instance, who have acquired the sample from the individual), or directly from
archival repositories.
Informatics: A global term used to describe a collection of modern, usually
"high
throughput" and computer-based scientific techniques that provide, generate,
accumulate, and/or
particularly analyze information about the genotypic and/or phenotypic and/or
metabolic state of a
cell or organism. Such techniques include genomic analyses and proteomic
analyses, as well as
metabolomic analyses. Informatics represents a subtle, but significant, shift
in perspective among
biologists. Whereas historically, scientists were accustomed to simplifying
their systems to make
metabolic interpretations, informatics allows scientists to embrace biological
complexity and to make
metabolic or phenotypic inference on the basis of as much information as
possible. Genomics has
brought to us the concept of high throughput science, and as a result, it has
demonstrated the power of
non-targeted and unbiased data acquisition. Although non-targeted data
acquisition is uncommon in
metabolite analysis, it does not violate the hypothesis-oriented procedure for
scientific study. Rather,
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-6-
high-throughput and non-targeted data acquisition simply allows scientists to
test their specific
hypotheses on a larger, non-biased dataset. This investigative process
functions differently than in a
traditional reductionist approach, where experiments are designed to address
single questions.
Informatics focuses on obtaining accurate data that can be integrated with
other datasets so that future
hypotheses can be tested on a database in silieo rather than at the laboratory
bench. This method of
investigation is suited to genomics, where sequences from disparate sources
are integrated easily into
one database because the genetic code is essentially universal. Because
metabolomic data is
influenced by the environment, and can be different depending on the time and
conditions under
which the sample is taken, a metabolomic database involves providing for
considerably more
complexity than is seen in a genomic database.
Lipid: As used herein, the term lipid refers to a class of water-insoluble,
oily or greasy
organic substances, that are extractable from cells and tissues by nonpolar
solvents, such as
chloroform or ether. The most abundant kinds of lipids are the fats or
triacylglycerols, which are
major fuels for most organisms. Another class of lipids is the polar lipids,
which are major
components of cell membranes. The following table (Table 1) provides one way
of grouping major
types of lipids; these have been grouped according to their chemical
structure:
Table 1:
Li id a Re resentative exam les or sub-grou
s
Triac 1 1 cerols_
Waxes
Phosphoglycerideshos hand lethanolamine
hos hatid lcholine
hos hand lserine
hos hand linositol
cardioli in
Sphingolipids s hin om elfin
cerebrosides
an liosides
Sterols and (see Table 3)
their fatty
acid esters
Lipid metabolites may also be broken down into other recognized classes, such
as those shown in
Table 2:
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
Table 2:
SCIENTIFIC NAME ABBREVIATION
Lyso-PhosphatidylcholineLY
Sphingomyelin SP
Phosphatidylcholine PC
Phosphatidylserine PS
Phosphatidylinositol PI
PhosphatidylethanolaminePE
Cardiolipin CL
Free Fatty Acids FFA
Monoacylglycerides MAG
Diacylglycerides DAG
Triacylglycerides TAG
Cholesterol Esters CE
Phosphatidic acids PA
Phosphatidylglycerols PG
CDP-diacylglycerols CDP-DAG
Lysocardiolipin LyCL
LysophosphatidylethanolamineLyPE
Specific subclasses (or groups of classes) of lipids can be distinguished
based on the position of the
fatty acids on the lipid back bone. For instance, the following are
positionally specific isomers of
lyso-lipid classes: 1-acyl, 2-lyso-x (where x is PC, PS, PE, PI, PG, or PA); 1-
lyso,2-acyl-x (here x is
PC, PS, PE, PI, PG, or PA); 1-acyl, 2,3-lyso-monoacylglyceride; 1-lyso, 2-
acyl, 3-lyso-
monoacylglyceride; 1,2-acyl diacylglydceride; and 1,3-acyl diacylglyceride.
Also included in the term lipid are the compounds collectively known as
sterols. Table 3
shows representative sterols.
Table 3:
SCIENTIFIC NAME MOLECULAR COMMON NAME
FORMULA
5b-cholestan-3b-of Cz~H480 coprostanol
5a-cholestan-3b-of Cz~H4s0 dihydrocholesterol
5-cholesten-3b-of Cz~H460 cholesterol
5,24-cholestadien-3b-of Cz~H440 desmosterol
5-cholestan-25a-methyl-3b-ofCz8H4z0 campesterol
5-cholestan-24b-methyl-3b-ofCz8H4z0 dihydrobrassicasterol
5-cholesten-24b-ethyl-3b-ofCz9Hso0 b-sitosterol
5,22-cholestadien-24b-ethyl-3b-ofCz9H4s0 stigmasterol
Metabolite: A biomolecule that has a functional and/or compositional role
(such as a
component of a membrane) in a biological system, and which is not a molecule
of DNA, RNA, or
protein. Examples of metabolites include lipids, carbohydrates, vitamins, co-
factors, pigments, and
so forth. Metabolites can be obtained through the diet (consumed from the
environment) or
synthesized within an organism. Genes and proteins exist in large part to
break down, modify, and
synthesize metabolites. Metabolites are not only directly responsible for
health and disease, but their
presence in a biological system is the result of a variety of factors
including genes, the environment,
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
_g_
and direct nutrition. By profiling the metabolite composition of a biological
sample, for instance
using the methods described herein, data on genotype, metabolism, and diet can
be obtained in great
detail. This data can be linked to clinical information and used to identify
the true biochemical basis
for health and disease.
Lipids are perhaps the most important subset of metabolites, because dietary
lipids and lipid
metabolism are clearly linked to the incidence and progression of several
major degenerative
diseases, including heart disease, diabetes, obesity, auto-immunity, and
chronic inflammation.
Moreover, because lipids are the only major nutrients that survive digestion
intact, highly accurate
information on individual nutrition can be gained from a lipid metabolite
profile. Thus, a lipid
metabolomic approach provides information encompassing the entire spectrum of
factors that
influence disease.
Each fatty acid may be found as a component of any lipid class, and in such
combination is a
different metabolite than it is on its own (free) or as a component in any
other lipid class. Thus,
palmitoleic acid in cholesterol esters is a distinct metabolite from
palmitoleic acid in
triacylglycerides, and so on. By way of example, if a system is used in which
lipids are categorized
into 17 classes (as shown in Table 2), and there an analysis determines the
concentration of 38 fatty
acids and sterols are determined in each class, then 17 x 38, or 646 specific
metabolite concentrations
may be determined.
Metabolomics: Highly parallel acquisition, databasing, and analysis of
metabolite levels in
a biological sample. In some instances, the sample is obtained from a subject
or individual currently
experiencing or being maintained under one or more defined condition(s). There
are several levels of
metabolomics - these can be differentiated for instance based on the scope of
the individual
metabolite profile, where scope refers to the number or type of metabolites
measured in the individual
analysis. Thus, lipid metabolomics is the study or analysis of a set of
individual lipid metabolites.
Carbohydrate metabolomics is the study or analysis of a set of individual
carbohydrate metabolites.
The set of data produced from analysis of an individual sample is referred to
herein as a individual
lipid metabolite/metabolic profile ("lipomic profile") of that sample. Certain
examples of lipid
metabolite profiles include a highly comprehensive set of metabolite
measurements (a profile) by
multi-parallel analyses.
The comparison of two metabolite profiles of similar scope (i.e., containing
information
about the same or a similar or overlapping set or subset of metabolites) from
cells/tissues/subjects
that have been differently treated, or that are genetically different or
different based on disease state
or condition, provides information on the metabolic effects of the difference.
A metabolome is a data set that includes levels of metabolites in a biological
system (e.g., a
cell, tissue, biological fluid, or whole subject) under specific conditions; a
multidimensional
metabolome includes such data from like samples over a variety of conditions
(e.g., time points,
treatment points, different drug or other treatments, and so forth).
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-9-
Quantitative metabolomic data as discussed herein include molar quantitative
data, mass
quantitative data, and relational data by either moles or mass (mole % or
weight %, respectively) for
individual metabolites, or subsets of metabolites. Quantitative aspects of
metabolomic samples may
be provided and/or improved by including one or more quantitative internal
standards during the
analysis, for instance one standard for each lipid class (in a lipomic
profile). Internal standards
employed in the methods described herein enable true quantification of each
fatty acid from each
lipid class, whereas traditional lipid analysis methods produce data in either
a percent-of total format
or as a mixed population of lipid metabolites. Provided internal standards are
designed to reflect any
loss of fatty acid due to oxidation, discrimination, or cross-contamination.
Using methods described herein, quantitative data can be integrated from
multiple sources
(for instance, samples generated from different labs, samples from different
subjects, or merely
samples processed on different days) into a single seamless database,
regardless of the number of
metabolites measured in each discrete, individual analysis.
Metabolite fingerprint (or linked profile): A distinct or identifiable pattern
of metabolite
levels, for instance a pattern of high and low metabolites of a defined set,
such as a biogenerative
pathway. In specific embodiments, the metabolite levels in the fingerprint are
absolute metabolite
concentrations. Metabolite fingerprints (also referred to as linked profiles,
e.g., a disease-linked
profile or toxin-linked profile) can be linked to a tissue or cell type, to a
particular stage of normal
tissue growth or disease progression, to a dietary limitation or
supplementation, or to any other
distinct or identifiable condition that influences metabolite levels (e.g.,
concentrations) in a
predictable or associatable way. Metabolite fingerprints can include relative
as well as absolute
levels of specific metabolites, but absolute levels (e.g., concentrations) are
preferred in many
embodiments. Specific examples of metabolite fingerprints are lipid metabolite
fingerprints.
Pharmaceutical/therapeutic agent: Any agent, such as a protein, peptide (e.g.,
hormone
peptide), other organic molecule or inorganic molecule or compound, or
combination thereof, that has
one or more effects on a biological system, such as a desired therapeutic or
prophylactic effect when
properly administered to a subject.
Quantified metabolic profile: A set of quantified measurements of one or more
metabolites. The profile usually contains more than one quantified
measurements for a metabolite
and provides a metabolic snap shot of a condition. Specific examples of
quantified metabolic profiles
are specific for a condition to which an organism is subject, such as a
genotype, for instance a
knockout of a specific gene; a dietary limitation or supplementation; a
disease or disease state; a
treatment with a compound, for instance a drug, toxin, suspected toxin,
pharmaceutical agent, or I
compound that is a candidate for a pharmaceutical agent, and so forth.
Quantified measurement of a metabolite: A measurement of the concentration of
a
metabolite, obtained by using an internal standard for the metabolite. The
measurement is usually
readily comparable with any other measurements of the metabolite, e.g., from a
different sample from
a same or different organism, which different organism is subject to the same
or a different condition,
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-10-
or samples generated using a different method or approach for obtaining the
measurements. The
quantified measurements can be integrated from multiple sources (whether it is
work from different
labs, samples from different subjects, or merely samples processed on
different days) into a single
database, regardless of the number of metabolites measured in each discrete,
individual analysis. For
example, quantified measurements of a lipid generally include measurements of
the concentration of
the lipid within each lipid class using one or more internal standards for
each lipid class. The
measurements can be compared with any other measurements of the lipid
regardless how the
measurements were obtained and can be integrated into one database readily
searchable for useful
indications or patterns.
Subject: Living mufti-cellular vertebrate organisms, a category that includes
both human
and non-human mammals.
Unless otherwise explained, all technical and scientific terms used herein
have the same
meaning as commonly understood by one of ozdinary skill in the art to which
this invention belongs.
The singular terms "a," "an," and "the" include plural referents unless
context clearly indicates
otherwise. Similarly, the word "or" is intended to include "and" unless the
context clearly indicates
otherwise. Hence "comprising A or B" means include A, or B, or A and B. It is
further to be
understood that all base sizes or amino acid sizes, and all molecular weight
or molecular mass values,
given for metabolites, nucleic acids or polypeptides are approximate, and are
provided for description.
Although methods and materials similar or equivalent to those described herein
can be used in the
practice or testing of the present invention, suitable methods and materials
are described below. All
publications, patent applications, patents, and other references mentioned
herein are incorporated by
reference in their entirety. In case of conflict, the present specification,
including explanations of
terms, will control. In addition, the materials, methods, and examples are
illustrative only and not
intended to be limiting.
11L Overview of Several Enzbodiznezzts
One embodiment is a method of generating a quantitative metabolomic database,
which
includes generating a plurality of quantitative metabolite profiles from a
plurality of biological
samples and assembling the plurality of metabolite profiles into a database.
Biological samples for
such methods may be selected from individual subjects and/or archival
repositories, and may be
acquired directly from individuals, from clinicians, or from archival
repositories directly. In specific
examples, the biological samples are taken from animals, for instance humans,
mice, rats, monkeys,
chickens, cats, dogs, pigs, horses, cows, fruit flies, or worms.
Also disclosed are methods of providing a metabolomic profile database. In
certain
embodiments, the metabolomic profile database is a lipomic profile database.
One such method
involves collecting a biological sample, performing quantitative lipid
metabolite analysis on it to
generate a lipomic profile for the sample, entering the lipomic profile into
one or more tables (for
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-11-
instance, a table on a computer), and repeating these steps a plurality of
times. The plurality of data
entries in the tables) is a lipomic database.
Also provided are methods of permitting (for instance, for a fee) access to
the metabolomic
profile databases described herein. Examples of such methods involve
embodiments in which access
is through a computer interface, for instance from a remote computer across
the Internet to the
computer that contains the database itself.
Further embodiments are methods of generating quantitative lipomic data.
Certain of such
methods include separating a biological sample into fractions based on a
plurality of lipid classes, and
measuring the quantity of a plurality of lipid metabolites in the fractions.
Either separating or
measuring in these methods may involve a chromatographic method, such as thin-
layer, gas and/or
liquid chromatography. The plurality of lipid classes may include, for
instance, phospholipids,
glycerides, and other lipids. An alternative division of lipids into class may
be as follows: lyso-
phosphatidylcholines, sphingomyelins, phosphatidylcholines,
phosphatidylserines,
phosphatidylinositols, phosphatidylethanolamines, cardiolipins, free fatty
acids, monoacylglycerides,
diacylglycerides, triacylglycerides, and cholesterol esters. In examples of
these methods, at least one
quantitative internal standard is included for each lipid class.
In the methods described herein, lipid metabolites may include tetradecanoic
acid,
pentadecanoic acid, hexadecanoic acid, heptadecanoic acid, octadecanoic acid,
eicosanoic acid,
docosanoic acid, tetracosanoic acid, 9-tetradecenoic acid, 9-hexadecenoic
acid, 11-octadecenoic acid,
9-octadecenoic acid, 11-eicosenoic acid, 5,8,11-eicosatrienoic acid, 13-
docosenoic acid, 15-
tetracosenoic acid, 9,12,15-octadecatrienoic acid, 6,9,12,15-
octadecatetraenoic acid, 11,14,17-
eicosatrienoic acid, 8,11,14,17-eicosictetraenoic acid, 5,8,11,14,17-
eicosapentaenoic acid,
7,10,13,16,19-docosapentaenoic acid, 4,7,10,13,16,19-docosahexaenoic acid,
6,9,12,15,18,21-
tetracoshexaenoic acid, 9,12-octadecadienoic acid, 6,9,12-octadecatrienoic
acid, 11,14-eicosadienoic
acid, 8,11,14-eicosatrienoic acid, 5,8,11,14-eicosicatetraenoic acid, 13,16-
docsadienoic acid,
7,10,13,16-docosicatetraenoic acid, 4,7,10,13,16-docosapentaenoic acid, 9-
trans-hexadecenoic acid,
9-trans-octadecenoic acid, 8-eicosaenoic acid, 5-eicosaenoic acid, plasmalogen
fatty acids, 5b-
cholestan-3b-ol, 5a-cholestan-3b-ol, 5-cholesten-3b-ol, 5,24-cholestadien-3b-
ol, 5-cholestan-25a-
methyl-3b-ol, 5-cholestan-24b-methyl-3b-ol, 5-cholesten-24b-ethyl-3b-ol, or
5,22-cholestadien-24b-
ethyl-3b-ol, for instance. Individual fatty acids may be found as a component
of any lipid class, and
in such combination is a different metabolite than it is on its own (free) or
as a component in any
other lipid class. Thus, palmitoleic acid in cholesterol esters is a distinct
metabolite from palmitoleic
acid in triacylglycerides, and so on.
Further provided embodiments are methods for presenting analysis of a
plurality of
individual lipid metabolite profiles, which methods involve designating the
plurality of individual
metabolite profiles (for instance, from within a cumulative database of such
profiles), identifying at
least one difference or at least one similarity in a metabolite in the
plurality of individual metabolite
profiles, and displaying at least one difference or at least one similarity in
a metabolite in the plurality
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-12-
of individual metabolite profiles. In specific examples of such embodiments,
the displaying
generates a web page for viewing. Such viewable web page may include, for
instance, a
representation of metabolite differences or similarities in the form of a heat
map or targeting chart, or
both.
Lipomic databases as described herein can be used in disease diagnosis,
prognosis, or
prediction, for instance by screening the lipomic database for a lipid
metabolite fingerprint that is
linked to the disease. These methods are also encompassed herein.
Further provided methods include methods of determining a metabolic effect of
a condition
(such as a genotype, for instance a knockout of a specific gene; a dietary
limitation; a disease or
disease state; a treatment with a compound, for instance a drug, toxin,
suspected toxin,
pharmaceutical agent, or compound that is a candidate for a pharmaceutical
agent) on a subject.
Examples of such methods involve subjecting the subject to the condition,
taking at least one
biological sample from the subject (usually after they are subjected to the
condition), analyzing the
biological sample to produce a test lipomic profile for the subject, comparing
the test lipomic profile
for the subject with a control lipomic profile, and drawing conclusions about
the metabolic effect of
the condition based on differences or similarities between the test lipomic
profile and the control
lipomic profile. The control lipomic profile may be for instance a compiled
lipomic profile
assembled from a plurality of individual lipomic profiles, or a pre-condition
(e.g., pre-treatment)
lipomic profile from the subject.
Specific examples of such methods are methods of determining the effectiveness
of drug or
treatment in a subject, for instance treatment with a hormone or a drug or
other treatment that relates
to controlling obesity or diabetes. Generally, in these methods a drug or
treatment is applied to the
subject, a biological sample is taken from the subject, and the biological
sample is analyzed to
produce a test lipomic profile for the subject. This test lipomic profile for
the subject is compared
with a control lipomic profile (such as the control lipomic profiles discussed
above), and conclusions
are drawn about the effectiveness of the drug or treatment based on
differences or similarities
between the test lipomic profile and the control lipomic profile.
Also provided are methods of determining likelihood of success of a treatment
or procedure,
such as an organ transplant. In such methods, the subject is subjected to the
treatment or procedure,
and a biological sample is taken from the subject. The biological sample is
analyzed to produce a test
lipomic profile for the subject, which is then compared with a control lipomic
profile. Conclusions
about the likelihood of success of a treatment or procedure are then drawn
based on differences or
similarities between the test lipomic profile and the control lipomic profile.
A further embodiment is a method of screening for a compound useful in
treating, reducing,
or preventing a disease or progression of a disease, comprising determining if
application of a test
compound alters a disease-related lipid metabolite profile so that the profile
less closely resembles a
disease-linked profile than it did prior to such treatment, and/or more
closely resembles a non-disease
profile (one from a subject, individual, or sample taken therefrom, where the
subject or individual
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-13-
does not have the disease or condition). A compound that so alters the disease-
related lipid
metabolite profile is then selected, for instance for further testing or other
study. Examples of such
disease-related lipid metabolite profile include a level of at least one of
the following metabolites (as
a free fatty acid, or as a component of any lipid class): tetradecanoic acid,
pentadecanoic acid,
hexadecanoic acid, heptadecanoic acid, octadecanoic acid, eicosanoic acid,
docosanoic acid,
tetracosanoic acid,9-tetradecenoic acid, 9-hexadecenoic acid, 11-octadecenoic
acid,9-octadecenoic
acid, 11-eicosenoic acid, 5,8,11-eicosatrienoic acid, 13-docosenoic acid, 15-
tetracosenoic acid,
9,12,15-octadecatrienoic acid, 6,9,12,15-octadecatetraenoic acid, 11,14,17-
eicosatrienoic acid,
8,11,14,17-eicosictetraenoic acid, 5,8,11,14,17-eicosapentaenoic acid,
7,10,13,16,19-
docosapentaenoic acid, 4,7,10,13,16,19-docosahexaenoic acid, 6,9,12,15,18,21-
tetracoshexaenoic
acid, 9,12-octadecadienoic acid, 6,9,12-octadecatrienoic acid, 11,14-
eicosadienoic acid, 8,11,14-
eicosatrienoic acid, 5,8,11,14-eicosicatetraenoic acid, 13,16-docsadienoic
acid, 7,10,13,16-
docosicatetraenoic acid, 4,7,10,13,16-docosapentaenoic acid, 9-trans-
hexadecenoic acid, 9-trans-
octadecenoic acid, 8-eicosaenoic acid, 5-eicosaenoic acid, plasmalogen fatty
acids, 5b-cholestan-3b-
0l, 5a-cholestan-3b-ol, 5-cholesten-3b-ol, 5,24-cholestadien-3b-ol, 5-
cholestan-25a-methyl-3b-ol, 5-
cholestan-24b-methyl-3b-ol, 5-cholesten-24b-ethyl-3b-ol, or 5,22-cholestadien-
24b-ethyl-3b-ol.
Also provided are computer-readable media having contained thereon a
metabolomic
database, wherein the database contains a plurality of records, each record
including quantitative data
for a plurality of metabolites from a biological sample. In specific examples,
the metabolomic
database is a lipomic database, and each record of the lipomic database
includes quantitative data for
a plurality of lipid metabolites from a biological sample, such as a sample
taken from an individual,
organism or subject undergoing or suffering from or subject to a condition.
Biological samples may
include samples from any or all of representative microbes, plants, or animals
(e.g., humans, mice,
rats, monkeys, chickens, cats, dogs, pigs, horses, cows, fruit flies, or
worms.).
Another embodiment is a database generated using methods described herein,
where the
database containing a profile table including a quantified metabolic profile
from a biological sample
from an individual having a condition, wherein the quantified metabolic
profile includes a quantified
measurement of a metabolite (or more than one metabolite) and wherein the
quantified measurement
is obtained using an internal standard (such as those described herein) for
the metabolite so that the
quantified measurement is integratable into a database. Metabolites measured
and quantified in the
metabolic profiles may be, for instance, lipids, carbohydrates, vitamins, co-
factors, and pigments.
It is contemplated that, in some embodiments, biological samples in this
context will include
a biological fluid or tissue sample. Biological samples in some embodiments
are selected from
individual subjects or archival repositories, or some of both, or from animal
models. In some
examples, at least some of the biological samples used to generate the
database are samples taken
from an animal, for instance, a human, mouse, rat, monkey, chicken, cat, dog,
pig, horse, cow, fruit
fly, or worm. Specific databases contain profiles generated from biological
samples from different
species, different analysis methods, etc.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-14-
In addition, it is specifically contemplated that some samples are obtained
from an organism
that is subject to a condition. For instance, the condition can include a
trait (such as a genotype, for
instance a genetic knockout or other mutation) of the organism from which the
biological sample is
obtained; a dietary limitation or supplementation; a disease or disease state;
application of a toxin or
suspected toxin; application of a pharmaceutical or therapeutic agent or
candidate agent to the
organism; an increase in exercise, a decrease in exercise, or a change in an
exercise regimen of the
subject; or some combination of these circumstances.
In particular embodiments, the databases contains lipid metabolite data,
wherein at least one
quantified lipid metabolite is selected from the group consisting of
tetradecanoic acid, pentadecanoic
acid, hexadecanoic acid, heptadecanoic acid, octadecanoic acid, eicosanoic
acid, docosanoic acid,
tetracosanoic acid, 9-tetradecenoic acid, 9-hexadecenoic acid, 11-octadecenoic
acid, 9-octadecenoic
acid, 11-eicosenoic acid, 5,8,11-eicosatrienoic acid, 13-docosenoic acid, 15-
tetracosenoic acid,
9,12,15-octadecatrienoic acid, 6,9,12,15-octadecatetraen~ic acid, 11,14,17-
eicosatrienoic acid,
8,11,14,17-eicosictetraenoic acid, 5,8,11,14,17-eicosapentaenoic acid,
7,10,13,16,19-
docosapentaenoic acid, 4,7,10,13,16,19-docosahexaenoic acid, 6,9,12,15,18,21-
tetracoshexaenoic
acid, 9,12-octadecadienoic acid, 6,9,12-octadecatrienoic acid, 11,14-
eicosadienoic acid, 8,11,14-
eicosatrienoic acid, 5,8,11,14-eicosicatetraenoic acid, 13,16-docsadienoic
acid, 7,10,13,16-
docosicatetraenoic acid, 4,7,10,13,16-docosapentaenoic acid, 9-trans-
hexadecenoic acid, 9-trans-
octadecenoic acid, 8-eicosaenoic acid, 5-eicosaenoic acid, plasmalogen fatty
acids, 5b-cholestan-3b-
0l, 5a-cholestan-3b-ol, 5-cholesten-3b-ol, 5,24-cholestadien-3b-ol, 5-
cholestan-25a-methyl-3b-ol, 5-
cholestan-24b-methyl-3b-ol, 5-cholesten-24b-ethyl-3b-ol, and 5,22-cholestadien-
24b-ethyl-3b-ol,
each as a compound or a component of a lipid molecule.
Also encompassed herein is a database wherein the quantified metabolic profile
includes a
quantified measurement of a lipid in a lipid class. For instance, the
quantified measurement of a lipid
in a lipid class is in some instances obtained using an internal standard for
the lipid class.
In some instances, a quantified lipid is selected from the group consisting of
fatty acid 16:0,
18:0, 16:1n7; 18:1n7; 18:1n9; 18:3n3; 20:5n3; 22:5n3; 22:6n3; 18:2n6; 18:3n6;
20:3n6; and 20:4n6,
each as a compound or a component of a lipid molecule. Other examples of
lipids include a sterol
selected from the group consisting of 5b-cholestan-3b-ol, 5a-cholestan-3b-ol,
5-cholesten-3b-ol, 5,24-
cholestadien-3b-ol, 5-cholestan-25a-methyl-3b-ol, 5-cholestan-24b-methyl-3b-
ol, 5-cholesten-24b-
ethyl-3b-ol, and 5,22-cholestadien-24b-ethyl-3b-ol, each as a compound or a
component of a lipid
molecule.
Lipid classes include lyso-phosphatidylcholine, sphingomyelin,
phosphatidylcholine,
phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine,
cardiolipin, free fatty acids,
monoacylglycerides, diacylglycerides, triacylglycerides, and cholesterol
esters, for instance.
Representative examples of such internal standards are provided herein, as is
teaching to
make internal lipid standards more generally. A particular embodiment is a
database as described
above, wherein at least one internal standard is selected from the group
consisting of diheptadecanoyl
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-15-
phosphatidylcholine, dipentadecaenoyl phosphatidylethanolamine,
tetraheptadecenoyl cardiolipin,
diheptadecenoyl phosphatidylserine, pentadecenoyl sphingomyelin, heptadecanoyl
lyso-
phosphatidylcholine, tripheptadecaenoyl glyceride, pentadecaenoic acid,
heptadecanoic cholesterol
ester and free fucosterol. In other specific embodiments, the internal
standard is heptadecanoic 1-
heptadecanoyl-2-lyso-phosphatidycholine for the lipid class of
lysophospholipids, N-pentadecenoyl-
D-erythro-sphingosylphorylcholine for the lipid class of sphingomyelin, 1,2
diheptadecanoylphosphatidylcholine for the lipid class of phosphatidylcholine,
1,2-
diheptadecenoylphosphatidylethanolamine for the lipid class of
phosphatidylethanolamine, 1,2-
diheptadecenoylphosphatidylserine for the lipid class of phosphatidylserine,
pentadecaenoic acid for
the lipid class of free fatty acids, triheptadecaenoic acid for the lipid
class of triacylglycerides,
1,1',2,2'-tetraheptadecaenoyl cardiolipin for the lipid class of cardiolipin,
cholesteryl heptadecanoate
for~the lipid class of cholesterol esters and stigmasterol for the lipid class
of free sterols.
Also provided is a computer readable medium containing a database as described
herein.
One example of such a computer readable medium is one where the metabolomic
database is a
lipomic database, and wherein at least one record comprises quantitative data
for a plurality of lipid
metabolites from a biological sample. Examples of such databases include those
in which the
database comprises records that comprise data from animal (e.g., humans, mice,
rats, monkeys,
chickens, cats, dogs, pigs, horses, cows, fruit flies, or worms), plant, or
microbial samples.
Also described herein are databases that further include a sample item table
including a
sample record for the quantified metabolic profile, and a condition item table
including a condition
record for the quantified metabolic profile. Specific examples of such
databases further comprise a
genomic item table including a genomic profile for the quantified metabolic
profile. Other specific
examples further comprise an expression item table including a gene expression
profile for the
quantified metabolic profile, and/or a protein item table including a
proteomic profile for the
quantified metabolic profile, and/or a character item table including a
character profile for the
quantified metabolic profile, and/or a filter item table including a filter of
quantified metabolic profile
for a desired condition.
Another embodiment is a user interface for operatively working with a
processor to affect
operation of a database as provided herein, where the user interface includes
means for providing
settings for selecting a set of samples, means for providing settings for
selecting a set of conditions,
means for providing settings for selecting a set of metabolites, and means for
displaying quantified
metabolic profiles corresponding to the selected samples and conditions,
wherein each displayed
quantified metabolic profile consists of the quantified measurements of the
selected metabolites.
Optionally, the user interface can further include a display area which
displays the value of a
quantified measurement of a metabolite within the quantified metabolic
profiles of the selected
samples and conditions. Optionally, the user interface can further include
means for comparing
quantified metabolic profiles corresponding to a first set of selected samples
and conditions to the
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-16-
quantified metabolic profiles corresponding to a second set of selected
samples and conditions, and
means for displaying the comparison.
Specific examples of the encompassed user interfaces include, for a plurality
of metabolites,
a presentation of an observed quantity of at least one metabolite for a first
biological sample with
respect to an observed quantity of the at least one metabolite for a second
biological sample, wherein
the presentation is operable to accept a user indication that further
information is desired with respect
to a selected metabolite.
Another embodiment is a computer implemented method for operating a relational
database
which method involves creating a profile table including a quantified
metabolic profile from a
biological sample from an individual having a condition, wherein the
quantified metabolic profile
comprises a quantified measurement of a metabolite and wherein the quantified
measurement is
obtained using an internal standard for the metabolite so that the quantified
measurement is
integratable into a database, creating a sample item table including a sample
record for the quantified
metabolic profile, creating a condition item table including a condition
record for the quantified
metabolic profile, and storing data in the profile table, the sample item
table, and the condition item
table, wherein each quantified metabolic profile corresponds to a sample
record and a condition
record.
Yet a further embodiment is a computer system for analyzing quantitative lipid
metabolomic
information, which system includes a processor; and a storage medium storing a
relational database
accessible by the processor, wherein the storage medium has stored thereon:
the relational database
comprising: a first table including a plurality of records, wherein at least
one of the records includes
quantitative data for a plurality of lipid metabolites. Specific examples of
such computer systems
include a processor, and a storage medium storing a relational database
accessible by the processor,
wherein the storage medium having stored thereon a relational database
comprising a profile table
including a quantified metabolic profile from a biological sample of a
condition, wherein the
quantified metabolic profile comprises a quantified measurement of a
metabolite and wherein the
quantified measurement is obtained using an internal standard for the
metabolite so that the quantified
measurement is integratable into the relational database, a sample item table
including a sample
record for the quantified metabolic profile, and a condition item table
including a condition record for
the quantified metabolic profile.
Specific internal standards and internal standard compositions, which often
contain a
mixture of two or more internal standards, are also provided. By way of
example, another
embodiment is an internal standard composition for lipid analysis of a sample,
comprising a plurality
of lipid species, wherein at least one lipid species comprises at least one
monounsaturated fatty acid
of formula N:lnR, wherein N is an odd integer equal to or larger than three,
wherein R is any integer
equal to or less than N-1, and wherein at least one of the plurality of lipid
species is a free fatty acid, a
sphingomyelin, a cardiolipin, a phosphatidylethanolamine, a phosphatidic acid,
a
phosphytidylcholine, a phosphatidylserine, a phosphatidylinositol, a
phosphatidylglycerol, a
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-17-
monoacylglyceride, a diacylglyceride, a triacylglyceride, a sterol ester, or a
lysophospholipid. In
specific examples of these compositions, each lipid species comprises at least
one such
monounsaturated fatty acid.
In particular example internal standard compositions, at least one of the
monounsaturated
fatty acids in the standard is not present in the sample. In examples of such
compositions, each of the
monounsaturated fatty acids is not present in the sample.
Particular examples of these internal standard compositions will include at
least one lipid
species having at least one monounsaturated fatty acid, wherein N is 3, 5, 7,
9, 11, 13, 15, 17, 19, 21,
23, or 25.
Optionally, each of the plurality of lipid species in the internal standard
composition
represents a specific (for instance, a different) lipid class. In some
instances, each of the plurality of
lipid species in an internal standard is present in the composition at a
concentration equivalent to
(e.g., with an order of magnitude) the concentration of a sample lipid species
(for instance, the most
abundant, second most abundant, third most abundant, and so forth) from the
same lipid class as
represented by that lipid species. By way of example, the internal standard
compositions may include
at least three lipid species, at least three lipid species, at least four
lipid species, at least five lipid
species, at least eight lipid species, or at least three ten species or more.
In particular example compositions, at least one of the lipid species is a
lysophospholipid,
and the lysophospholipid has the formula 1-acyl,2-lyso-M or 1-lyso,2-acyl-M,
and where M is
phosphytidylcholine, phosphatidylserine, phosphatidylethanolamine,
phosphatidylinositol,
phosphatidylglycerol, or phosphatidic acid.
In still other particular example compositions, the lipid classes comprise
lyso-
phosphatidylcholines, sphingomyelins, phosphatidylcholines,
phosphatidylserines,
phosphatidylinositols, phosphatidylethanolamines, cardiolipins, free fatty
acids, monoacylglycerides,
diacylglycerides, triacylglycerides, cholesterol esters, phosphatidic acids,
phosphatidylglycerols,
CDP-diacylglycerols, lysocardiolipins, Iysophosphatidylethanolamines, or two
or more thereof.
Also provided is an internal standard for phosphatidylethanolamines,
phosphatidic acids,
phosphytidylcholines, phosphatidylserines, phosphatidylinositols,
phosphatidylglycerols,
diacylglycerides, or triacylglycerides, comprising a first fatty acid of
formula N:0 in the sn-1 position
and a second fatty acid of formula M:Y in the sn-2 position, where Y is an
integer greater than 0.
One specific example is an internal standard for phosphatidylethanolamines,
wherein the internal
standard comprises a phosphatidylethanolamine that comprises the first fatty
acid and the second
fatty acid. Another specific example is an internal standard for phosphatidic
acids, wherein the
internal standard comprises a phosphatidic acid that comprises the first fatty
acid and the second fatty
acid. Still another example is an internal standard for phosphytidylcholines,
wherein the internal
standard comprises a phosphytidylcholine that comprises the first fatty acid
and the second fatty acid.
Yet a further example is an~internal standard for phosphatidylserines, wherein
the internal standard
comprises a phosphatidylserine that comprises the first fatty acid and the
second fatty acid. Another
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-18-
example is an internal standard for phosphatidylinositols, wherein the
internal standard comprises a
phosphatidylinositol that comprises the first fatty acid and the second fatty
acid. Yet another example
is an internal standard for phosphatidylglycerols, wherein the internal
standard comprises a
phosphatidylglycerol that comprises the first fatty acid and the second fatty
acid. Another provided
example is an internal standard for diacylglycerides, wherein the internal
standard comprises a
diacylglyceride that comprises the first fatty acid and the second fatty acid.
Still another example is
an internal standard for triacylglycerides, wherein the internal standard
comprises a triacylglyceride
that comprises the first fatty acid and the second fatty acid. Optionally,
such an example internal
standard for triacylglycerides further includes a third fatty acid that is
different from the first fatty
acid and the second fatty acid.
Another embodiment is an internal standard for triacylglycerides or
cardiolipins, comprising
a first fatty acid of formula N:X at a first position, a second fatty acid of
formula M:Y at a second
position, and a third fatty acid of formula O:Z at a third position, wherein
N:X, M:Y, and O:Z are
different from each other. In some examples, the first position is sn-1 and X
is 0. In anther example,
at least Y or Z is 1, and in specific examples, both Y and Z are 1. For
instance, in one particularly
contemplated example of such an internal standard, N:X is 17:0, M:Y is 19:1,
and O:Z is 19:1 and
wherein the first position is sn-1, the second position is sn-2, and the third
position is sn-3. In
another, N:X is 17:0, M:Y is 19:1, and O:Z is 19:2 and wherein the first
position is sn-1, the second
position is sn-2, and the third position is sn-3. In still other examples, the
internal standard is an
internal standard for triacylglycerides, wherein the internal standard
comprises a triacylglyceride that
comprises the first fatty acid, the second fatty acid, and the third fatty
acid. In yet another example, it
is an internal standard for cardiolipins, wherein the internal standard
comprises a cardiolipin that
comprises the first fatty acid, the second fatty acid, and the third fatty
acid. For instance, in such an
internal standard for cardiolipins, the first position is sn-1, the second
position is sn-2, and the third
position is either sn-1' or sn-2'. By way of example, in one such internal
standard the third position
is sn-1', and X and Z are 0.
Also provided is an internal standard composition for lipid analysis of a
sample, comprising
a plurality of lipid species, wherein at least one lipid species comprises at
least one polyunsaturated
fatty acid of formula N:lnR, wherein N is an even integer equal to or larger
than six (for instance, 6,
8, 10, 12, 14, 16, 18, 20, 22, 24, or 26), wherein R is any integer equal to
or less than N-1, and
wherein the desaturations occur in positions different from the positions of
desaturations in fatty acids
present in the sample, and wherein at least one of the plurality of lipid
species is a free fatty acid, a
sphingomyelin, a cardiolipin, a phosphatidylethanolamine; a phosphatidic acid,
a
phosphytidylcholine, a phosphatidylserine, a phosphatidylinositol, a
phosphatidylglycerol, a
monoacylglyceride, a diacylglyceride, a triacylglyceride, a sterol ester, or a
lysophospholipid. In
specific examples of such internal standard compositions, each lipid species
comprises at least one
such polyunsaturated fatty acid.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-19-
In specific examples of these internals standard compositions, each of the
plurality of lipid
species represents a different lipid class. For instance, such compositions
can contain at least three
lipid species, at least four lipid species, at least five lipid species, at
least eight lipid species, at least
ten lipid species, or more.
In still other specific examples of the internal standard compositions, each
of the plurality of
lipid species is present in the composition at a concentration equivalent to
the concentration of a
sample lipid species from the same lipid class as represented by that lipid
species.
Also provided are specific internal standard compositions, wherein at least
one of the
polyunsaturated fatty acids is not present in the sample. In further examples,
each of the
polyunsaturated fatty acids in the internal standard is not present in the
sample.
By way of specific example, at least one of the lipid species in the internal
standard
compositions is a lysophospholipid, and the lysophospholipid has the formula 1-
acyl,2-lyso-M or 1-
lyso,2-acyl-M, and where M is phosphytidylcholine, phosphatidylserine,
phosphatidylethanolamine,
phosphatidylinositol, phosphatidylglycerol, or phosphatidic acid. In other
specific examples, the lipid
classes included in the internal standard composition include lyso-
phosphatidylcholines,
sphingomyelins, phosphatidylcholines, phosphatidylserines,
phosphatidylinositols,
phosphatidylethanolamines, cardiolipins, free fatty acids, monoacylglycerides,
diacylglycerides,
triacylglycerides, cholesterol esters, phosphatidic acids,
phosphatidylglycerols, CDP-diacylglycerols,
lysocardiolipins, lysophosphatidylethanolamines, or two or more thereof.
The internal standards described in this disclosure, including particular
single internal
standard molecules or combinations thereof or compositions containing such,
can be used with the
methods provided herein, particularly with the methods of generating
quantitative lipomic data.
IV. Metabolomicr
The vast potential of genomics and bioinformatics to identify genes that cause
disease by
investigating whole-genome databases is accepted. By comparing the analysis of
an individual's
genotype with a genomic database, medicine is expecting to personalize health
care by providing
drugs tailored to individual genotype. This same bioinformatic approach, when
applied to the study
of human metabolites, has the potential to identify and validate targets to
improve personalized health
through nutrition, pharmacology, environment, physical activity, and/or gene
therapy. Advances in
high-throughput analytical chemistry and computing technologies make the
creation of a vast
database of metabolites possible for several subsets of metabolites including
lipids and organic acids.
In creating integrative databases of metabolites for bioinformatic
investigation, the current
concept of single biomarker measurements must be expanded in three dimensions
in order to:
(1) include a highly comprehensive set of metabolite measurements (a profile)
by multi-
parallel analyses;
(2) measure individuals as a function of time rather than simply in the fasted
state; and
(3) integrate these metabolic profiles with genomic, expression and proteomic
databases.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-20- .
Substantial databases of metabolite concentrations will be predictive
resources to quantify
the relationship between metabolites and health. An overview of one way in
which a metabolomic
database can be used is shown in Figure 1. In this schematic drawing,
quantitative analysis is
performed to assess and measure the amounts of metabolites in a biological
sample. The output of
the analysis is subjected to optional transformation through one or more
calculation processes,
providing a set of numeric results. For instance, if the analysis is a
quantitative gas chromatograph,
the area under the curve can be measured and the relative area of each peak
determined. These
relative areas can be converted into absolute amounts for each individual
metabolite measured by the
inclusion of control compounds in the analysis, as described herein. The raw
and/or processed data
are entered into a database, for instance a cumulative database that contains
the results from a
multitude of different analyses. This database can be queried in order to
search for specific datasets
from within the database, and filters (such as those provided herein) can be
used to produce limited
output in interpretable forms. Such forms may be user interfaces that permit
continued interaction
with the database, and/or that permit access to more information than the raw
or processed results of
individual analyses or collections thereof. In certain embodiments, the output
from such a
metabolomic database may be graphical or statistical.
Quality control triggers may be included within the database, which flag
samples that are
outside of expected or predicted limits, or which otherwise trip a trigger so
that the user of the
database (and/or the individual entering the data, or a third party) is made
aware of that specific
sample. In specific embodiments, the tripping of such a trigger will indicate
that the corresponding
sample is in someway suspect, and the analysis for that sample may be
repeated.
The application of an informatic approach to the study of metabolites in
individuals
represents an important advance. Scientists currently view their goal as
ultimately reductionist and
strive to identify the single best biomarker that reflects phenotype. However,
single biomarkers have
shown very limited success in predicting chronic disease. This has led the
inventors to the realization
that there is a need for more global and integrated approaches for assessing
metabolism. Thus, the
study of metabolites must be redefined in parallel with genomic and proteomic
analyses, as the means
to allow researchers to measure a large number or even an entire set of
metabolites. The entire
metabolome, with all of its individual concentrations and quantitative infra-
relationships forms the
metabolic basis of a phenotype. Therefore, only a metabolomic approach can
accurately assess the
complex role of metabolites in defining individual health.
In part, the reluctance to study metabolism within the framework of
informatics arises from
the inherent complexity of metabolite profiling. Although expression analysis
and proteomics are
responsive to the environment and are thus more complex than genomics, they
are constrained, at
least in theory, by a factor of the number of genes present in an organism.
The overall metabolome is
not confined to the products of genes, and thus, the metabolome represents a
potentially massive
inclusive set of compounds. Further, a metabolite profile for a single
individual is neither constant
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-21-
among individual cells, nor is it stable over time. Implementing a metabolomic
research strategy
involves planning for considerable complexity. This disclosure provides
methods for generating
metabolomic profiles for individual samples, for sets or subsets of the
available metabolites, and
methods of assembling such profiles into integrated, comprehensive, minable
databases.
The ultimate application of these approaches, of course, is to generate
knowledge of
metabolism that is faithful to the overall phenotypes that accurately reflect
health, predispositions to
disease, or other health outcomes. In nutritional terms, for example,
understanding the variation in
metabolic responses to diet is the goal of the science of nutrition. Before
embarking on wholesale
renovations of agricultural products for nutritional improvement, metabolomics
is uniquely qualified
to address the questions that must be answered to succeed. Although the
development of this
technology is likely to be driven by human health concerns, rapid analysis of
lipids and other
metabolite classes can be used in the support of a variety of topics including
plant and animal
breeding, characterization of transgenic crops, and fundamental science.
Metabolomics will be a part
of the future of biotechnology, nutrition, and agriculture.
V. Lipid Metabolor~aics
By way of example, this disclosure focuses on analysis of lipid metabolites,
generation of
lipid metabolite profiles, lipid metabolomic databases, and the information
that can be mined from
such profiles and databases. In particular, methods are provided for
developing a metabolomic
database capable of producing predictive and diagnostic profiles of disease.
Figure 2 provides an overview of a lipid metabolomic analysis system.
Chromatographic
data is entered into a database, which can be mined for desired information
and presented in the form
of a graphical interface (for instance a heat map or targeting chart, as shown
in the second panel of
Figure 2). Such interfaces may be optionally provided in interactive form, for
instance on a computer
system, or remotely across the Internet or another computer communication
system. Data mined
from the cumulative lipid metabolite database can be used, for instance, for
clinical or diagnostic
testing (e.g., for a propensity to obesity or another biological condition
that impacts or is impacted by
lipid metabolism), or to identify specific metabolic targets of drugs, as
described in more detail
herein.
Present analytical methods, including those disclosed herein, can produce a
spectrum of data
easily developed into a metabolomic database. For instance, fatty acids,
glycerolipids, sterols, and
numerous bioactive lipid mediators (including products of epoxygenase,
lipoxygenase and
cyclooxygenase pathways) are quantifiable in biological samples. Thus, as
demonstrated clearly
herein, a few parallel analyses ars capable of defining an essentially
complete lipid profile of a
sample.
Lipids are an attractive subset of metabolites for metabolomic applications.
In addition to
their ubiquitous cellular functions as structural, energetic, and bioactive
signaling molecules, lipids
are reflective of both diet and metabolism. The major fatty acids in human
metabolism and the
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-22-
enzymes that modify them are depicted in Figure 3. Fatty acids are an
interesting subject matter for
metabolomics because they are the only major macronutrients to survive
digestion intact, and yet
humans possess the biochemical machinery to process dietary fatty acids
further into new forms of
fatty acid. As a result, the fatty acid composition of tissues and fluids
reflects the influence of both
diet and metabolism. By quantifying the fatty acids present in human plasma,
for example, a
researcher could determine the dietary preferences of that individual.
Alternatively, and perhaps
more interestingly, a researcher could assay endogenous lipid metabolism by
comprehensive lipid
analysis, because every lipid substrate and product is measured simultaneously
from a single sample.
Thus, a unique aspect of lipid metabolomic analysis is that the information
yielded by an experiment
reflects the ultimate expression of genomics, proteomics, and environment as a
lipid metabolome.
Because current technology allows for the comprehensive analysis of lipid
composition in a
sample, metabolic interpretations can be extended to the activities of the
enzymes that modify lipids.
Quantitative analysis of fatty acid concentration provides data on not only
the fatty acids but also on
the relative activities of the desaturases and elongases that modify them.
Moreover, a quantitative
analysis of fatty acids from individual glycerolipid classes yields data on
the mass of each
glycerolipid class, thereby enabling the investigation of pathways involved in
glycerolipid
metabolism. The ability to not only profile diseases, but also to identify the
complex metabolic
dysregulations involved in that disease, using the methods provided herein is
a major advance for
medicine.
The utility of metabolite profiling is not limited to making assessments about
the status of
individuals. Particularly, one advantage of metabolomics is the potential to
use a metabolomic
database as a tool for in silico investigations. The availability of such
databases will be particularly
helpful for applying bioinformatic approaches to nutrition, pharmacology, and
toxicology, because
once a metabolic profile is developed for a specific nutritional or otherwise
affected state, it can be
compared with the metabolomic database to determine the relationships among
diet, drugs, toxins,
treatments, genotype, and phenotype. The ability to mine large databases in
silico will be an
advantage of metabolomics to nutrition, because testing every conceivable
nutrient by single clinical
trials is not possible.
Moving from single biomarkers to metabolomic analysis is a necessary step
inasmuch as
many approaches to lowering the unilateral risk of one disease in an
individual simply increase the
risk of another disease in that individual. A pertinent example of this
problem is the change in
nutritional recommendations from high fat to high carbohydrate diets. It is
widely understood that
high fat diets increase serum low-density lipoproteins and thus the risk for
cardiovascular disease in
most individuals; however, high carbohydrate diets increase serum
triacylglycerides (Kasim-Karakas
et al., Am. J. Cliu. Nutri. 71:1439-1447, 2000) and the risk for
cardiovascular disease in a subset of
the population, particularly some women (Liu et al., Arn. J. Clin. Nutri.
71:1455-1461 2000). By
measuring every metabolite involved in lipid metabolism, subtle differences in
the predisposition or
progression of disease among individuals will be elucidated. The broader and
much more exciting
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-23-
aspect of this technology is thus the generation of metabolic profiles that
are not simply markers for
disease, but metabolic maps that can be used to identify specific genes or
activities influential in the
progression of disease or the maintenance of overall health. In this way,
metabolomics is a subset of
functional genomics. The value of genomic, expression, proteomic, and
metabolomic databases in
predicting phenotype will be enhanced dramatically by their horizontal
integration into global
bioinformatic databases.
VL Application of Lipid Metabolomics to Predictive Medicine
Relative to biomolecules, biochemical science has very few ways to quantify
phenotype.
Alternatively, medicine has, at its very core, a system for identifying,
categorizing and recording
phenotypic information about individuals. Because science has become
exceedingly adept at
quantifying large numbers of molecules at an astonishing rate of throughput,
science and medicine
should couple their expertise to develop this metabolite-phenotype
relationship. By developing a
database that (1) allows clinicians to input patient information and (2)
allows high-throughput science
to contribute analytical data, powerful new predictive and analytical tools
are enabled.
The data from a comprehensive lipid analysis produce information useful for
this purpose.
The applications of a quantitative lipid database are myriad. In one
variation, the data from
comprehensive lipid analyses are used to generate biomarkers of a selected
phenotype. These
biomarkers are not, as traditionally defined, single measurements, but rather
complex lipid metabolite
profiles that include a large number of metabolites and even relations between
metabolites. These
profiles, when compared between experimental groups, generate a series of
significant differences
that can be used to construct reliable database filters. A database filter is
essentially a way of
discriminating a set of subset of data, and selecting this data from the
database for instance for
display or further analysis. Simple filters can comprise as few as one
specified discriminating
variable, for instance the gender of the individual providing the sample, or
the age, or a treatment
compound. More complex filters, using more than one discriminating variable at
a time, are also
contemplated. In specific instances, the filter can include a list of the most
consistent and unique
metabolite concentrations or interactions that exist between experimental
groups (e.g., a filter can be
based on a profile, such as a condition-linked profile). These differences and
interactions are
determined by standard statistical methods.
Database filters for specific phenotypes can serve many purposes. First, using
discriminant
analysis or an analogous statistical technique, a database filter can identify
entries in a database that
match a phenotype of interest. This is an essential element to metabolomics
and informatics in
general, because it allows scientist to query a database of individuals that
were not specifically tested
for the phenotype of interest.
A second purpose for creating a list of reliable and unique differences
between experimental
groups (a database filter) is to identify the points in the lipid metabolism
pathways most closely
linked with a phenotype. As an example of this approach, a researcher might
perform an experiment
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-24-
to determine the complete lipid profile of patients with type II diabetes.
These data would be
recorded with all of the phenotypic and clinical information relevant to the
patient in a database. At a
later point in time, another researcher could generate metabolic profiles for
individuals consuming
different foods, such as dietary olive or fish oils, respectively, and enter
this information into the
same database. Both researchers would now have the ability to identify
groupings of patients that
match either diabetic or dietary profiles. Once the data are collected, it is
a simple matter of asking
the appropriate question irz silico to determine if there are relations
between dietary oil consumption
and diabetes. Additionally, the identified differences act as clues for the
metabolic basis of the effect.
There are innumerable advantages to an irz silico approach such as outlined
above, including
increased statistical power, the avoidance of cumbersome financial and
practical limitations to
experimentation, and the ability to re-assess data as new information emerges.
Subject matching,
dataset selection, and the grouping of experimental sets can all be done
through i~z silico querying. It
is expected that unanticipated relationships between diet, metabolism, and
phenotype will quickly
emerge.
V11. Metabolornics as Functional Genonzics
Another aspect of the provided technology is the generation of metabolic
profiles that are
not simply markers for disease, but are metabolic maps that can be used to
identify specific genes or
biochemical activities that cause or influence a disease state. Metabolomics
is in essence functional
genomics from metabolite analysis. By defining the metabolic basis for
phenotype using the
techniques described, extraordinary opportunities to understand and treat
diseases are provided.
Much in the same way that gene chips allow researchers to observe the complex
expression response
to a stimulus, metabolomics enables observation of the complex metabolic
interplay responsible for
defining phenotype.
By extending this approach beyond the observation of individual metabolic
dysregulations,
medicine will begin to profile not single diseases, but health. As health is
the proper balance of all
vital metabolic pathways, comprehensive or metabolomic analysis lends itself
to identifying
metabolite distributions necessary for health. Comprehensive and quantitative
analysis of lipids
provides this degree of diagnostic power to researchers and doctors interested
in mining metabolic
profiles, and databases containing a plurality of such profiles, for
biological meaning.
VIIL Samples afzd Sample Pr~ocessirz.g
Any sample that contains or may contain the metabolites of interest can be
used for the
analyses provided herein. For instance, samples suitable for inclusion in a
quantitative lipid
metabolite database include plasma, serum, tissues or cells from plants,
humans or research animals
(including mouse, rat, non-human primate, pig, chicken or other). The samples
may be those from
plants, humans or other animals, which may optionally have been subjected to
pharmacological,
genetic, toxicological or nutritional intervention. In other embodiments, the
samples are from
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-25-
humans or research animals expressing specific traits, for instance those
suffering from a disease or
condition, or displaying a level of athletic performance.
It is particularly contemplated herein that biological samples may be in vitro
cell cultured
samples, which have been subjected to differential treatment with drugs or
potential drugs, or with
any potentially useful pharmaceutical agent (for instance, which might be
contemplated as being
tested for use as a drug), or with a toxin or other stressor or organic or
inorganic substance that might
be expected to cause some change in the metabolome of the subject cell
culture.
The processing of individual samples will be governed at least in part by what
type of
sample is used. Methods of harvesting biological samples are well known to
those of ordinary skill
in the art, and those appropriate for use with the provided methods are
conventional. Methods for
preparing the harvested samples for analysis will be influenced by the
analysis being performed in
order to quantify the metabolites) of interest. Those of ordinary skill in the
art know systems that
can be used to isolate (at least relatively) specified classes of molecules.
Optionally, biological samples for use in the provided methods can be stored
prior to
preparation and analysis, for instance by freezing, for instance under
cryogenic conditions.
It is contemplated that sample preparation may be carried out by someone other
than the
party that carries out the analysis of metabolites in that sample. Thus, this
disclosure includes
systems in which a sample is harvested, processed at least to a point at which
it can be shipped to a
remote location, and then the processed (or partially processed) sample is
transported to a facility at
which the metabolites are assayed. By way of example, the samples may be
transported while frozen.
Likewise, the treatment of subjects prior to harvesting of biological samples
may be carried
out at the same facility that harvests the sample, but this is not necessary
for the methods described
herein.
IX. Individual Sample Afzalysis
Several aspects of lipid analysis have been modified, as provided herein, for
use in lipid
metabolomics. Currently, most fatty acid analyses are performed by gas
chromatography, a
technique that provides exquisite separation and quantification of analytes.
However, researchers
continue to report their results as a percentage of total fatty acids. Data in
this format are not
comparable between experiments, nor is it comparable between individual lipid
classes within an
experiment, and therefore are not integratable into a database. For example, a
scientist interested in
the metabolism of oleic acid could not determine the distribution of oleic
acid among lipid classes in
plasma from mole percentage or weight percentage data. For quantified
measurements of lipid
metabolomics as provided herein, data produced in each experiment is expressed
as a concentration,
for example, micrograms per milliliter, so that a consistent and comparable
database of lipids can be
assembled from multiple experiments.
In certain embodiments, the data includes quantitative measurements of the
fatty acids that
are organized (or can be organized) by lipid classes. Because lipid classes in
some embodiments are
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-26-
separated prior to fatty acid quantification, the composition of a sample is
determined in great detail.
The results of a single analysis may include the mass or concentration of more
than 35 individual
fatty acids from each lipid class present in the sample. The total mass or
concentration of the lipid
class also may be quantified.
Separation and quantitative data can be produced via chromatography using many
methods,
such as gas and liquid chromatography, including high-performance liquid
chromatography, thin
layer chromatography, capillary and gel electrophoresis, and combinations of
two or more of these
methods. See, for instance, methods described in various text and reference
analytic chemistry
books, such as chapters 22-24 of Quazzti.tative Chezrzicai Azzalysis by D.C.
Harris (W.H. Freeman and
Co., 4''', 1995; ISBN 0-7167-2508-8). Choice of separation and quantitation
methods may be
influenced by the metabolites being measured.
By way of example, the following methods can be used for generating
quantitative lipid
metabolite data from biological samples. The chromatographic conditions,
internal standard
compositions and amounts, derivatization reactions, extraction conditions,
sample amounts, and so
forth can be varied by those of ordinary skill in the art. The following
description provides an
overview of certain non-limiting methods that can be,used for analysis of
lipid metabolites in a
biological sample.
A. Lipid Analysis
Extraction: The lipids from various samples, such as plasma, serum, tissue, or
cells, can be
extracted using a fluid extractant comprising a non-polar component and a
polar component. By way
of example, lipids are extracted from plasma, serum, tissues, and cells by the
method of Folch et al.
(J. Biol. Clzezn. 226, 497-509, 1957). By way of example, about two hundred
microliters of plasma or
serum, or about 50 mg of tissues or cells are added to a homogenizes for a
single analysis, though
larger or smaller amounts can be used.
To each sample, the appropriate masses of internal standard such as those
provided herein
are added, as well chloroform:methanol (2:1 vol/vol). In general, the internal
standards are
compounds that share a lipid class with the target metabolites (i.e. an
internal standard for
triacylglyceride metabolites is itself a triacylglyceride), but have fatty
acids as constituents that are
not present in the sample being analyzed. An internal standard for any given
lipid class is selected to
behave sufficiently similarly to the target metabolites such that there is
essentially no discrimination
(selective loss or retention) of the internal standard relative to the target
metabolites at any step of the
analytical process before the analysis. The fatty acid moiety of the internal
standard compound will
also generally be different than the fatty acids present in the lipid class
analyzed from the sample, so
that the internal standard fatty acid can be separated completely from the
target compound fatty acids
by the analysis. According to specific provided embodiments, at least one
unique internal standard is
used for each class of lipid separated.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-27-
By way of example, the solution mixture consisting of sample, fluid
extractant, and internal
standards) is homogenized, for instance by twelve strokes with a ground-glass
homogenizer.
Following homogenization, potassium chloride (e.g., 1.8 m1 of 0.01 M) is
added, and the solution
vigorously mixed. The organic fraction containing the lipids and the internal
standards) is separated
from the polar fraction of the mixture by centrifugation. The lipid extract
can then be removed from
the mixture and, as needed, concentrated under a stream of nitrogen in
preparation for lipid class
separation.
Internal Standards: Internal standards for use in the provided methods may
take many
forms. In certain embodiments, lipid classes that separate adjacent to each
one another during lipid
class separation have internal standards that contain fatty acids that are
different than the fatty acids
within the internal standard of the adjacent lipid class. This allows one to
check for cross-
contamination and complete separation of lipid classes by looking for the
presence of the internal
standard of one lipid class in the analysis of the adjacent lipid class.
In some embodiments, saturated fatty acids are employed as internal standards
for the
analysis of sphingomyelin, lyso-phospholipids (provided they are 1-aryl-2-lyso-
phospholipids) and
cholesterol esters, while saturates and monounsaturated fatty acids are used
as internal standards for
diacylglycerides, monoacylglycerides and free fatty acids.
Optionally, the internal standards provided by the present disclosure are
added to each
sample such that the fatty acids derived from the internal standard prior to
the analysis are present at
concentrations that approximate the second most concentrated fatty acid in the
analyzed lipid class of
the biological sample. This helps to ensure that the internal standard
provides accurate data for
quantifying the fatty acids and, provided the concentration of the sample is
appropriate, that both the
analytes and the internal standard induce a response from the detector that is
within its linear and
quantitative range.
Various fatty acids are particularly contemplated as internal standards,
including fatty acid
saturates, e.g., 3:0, 5:0, 7:0, 9:0, 11:0, 13:0, 15:0, 17:0, 19:0, 21:0, 23:0,
25:0, and 27:0, and fatty acid
monounsaturates, e.g., 5:1, 7:1, 9:1, 11:1, 13:1, 15:1, 17:1, 19:1, 21:1,
23:1, and 25:1. In particular
embodiments, internal standards will include 17:0, 19:0, 15:1, 17:1 and 19:1.
In addition, polyunsaturated fatty acids may be used as internal standards,
provided that they
are odd-carbon numbered chains (e.g., 3:2, 5:2, 7:2, 9:2, 11:2, 13:2, 15:2,
17:2, 19:2, 21:2, 23:2, 25:2,
and 27:2, as well as 5:3, 7:3, 9:3, 11:3, 13:3, 15:3, 17:3, 19:3, 21:3, 23:3,
25:3, 27:3, and so forth for
additional unsaturations).
The position of unsaturated bonds) within the fatty acids) of a standard can
be varied to
produce a large variety of internal standard compounds. For instance, 15:1n7
and 15:1n9 are distinct
fatty acids that share highly similar physical properties. For instance, if
15:1 fatty acids provide the
physical properties that best mimic lipid classes that also happened to
separate next to each other
during lipid class separation, one of these two fatty acids (15:1n7 and
15:1n9) could be used in one
class, while the other fatty acid could be used in the second lipid class.
Thus,'because metabolite
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-28-
analysis is capable of separating 15:1n7 from 15:1n9, the degree of cross-
contamination or separation
of the two lipid classes could be determined. In general, it is useful if the
position of the double
bonds) in the fatty acids) is unique relative to the composition of the
biological sample, thus
facilitating distinguishing these compounds in the final analysis and/or
quantification.
In some embodiments, a mixture of internal standards is used to control
different aspects of
the analysis, e.g., positional specificity or compositional variation. For
example, complex lipids that
contain more than one fatty acid per molecule, such as phospholipids and
triacylglycerides, typically
contain defined types of fatty acids in specific positions on the lipid
molecule. For instance, saturated
fatty acids comprise more than 90% of the fatty acids on the sn-1 position
(the first carbon on the
glycerol backbone) of phosphatidylcholine in most biological samples, while
unsaturated fatty acids
comprise more then 95% of the fatty acids present in the sn-2 position of
phosphatidylcholine. Thus,
to improve the physical properties of an internal standard for
phosphatidylcholine, it may prove
useful to construct an internal standard molecule such that it contains a
saturated fatty acid in the sn-1
position and an unsaturated fatty acid in the sn-2 position. This approach can
be used to improve the
physical properties of the internal standard to better match those of natural
compounds.
Many types of chromatography can selectively deplete fatty acid molecules
based on the
number of double bonds present in the fatty acid, or on the number of carbons
in the fatty acid. By
constructing internal standards with a variety of fatty acids of varying
unsaturation and chain length,
these internal standards can control for these selectivities. For example, if
internal standards are
constructed with different fatty acids, e.g., with the different fatty acids
present on the same
glycerolipid molecule, such as triacylglyceride with a 17:0 on the sn-1
position, a 19:1 on the sn-2
position and a 19:2 on the sn-3 position, the extent of loss of fatty acids of
varying unsaturation or
chain length during analysis can be calculated and used to correct the final
data for improved
quantification. Thus panels of internal standards for each lipid class can be
constructed with
knowledge of the typical biological composition of the lipid class.
By way of specific example, this disclosure particularly contemplates internal
standards
including diheptadecanoyl phosphatidylcholine, dipentadecaenoyl
phosphatidylethanolamine,
tetraheptadecenoyl cardiolipin, diheptadecenoyl phosphatidylserine,
pentadecenoyl sphingomyelin,
heptadecanoyl lyso-phosphatidylcholine, tripheptadecaenoyl glyceride,
pentadecaenoic acid,
heptadecanoic cholesterol ester and free fucosterol, either individually or a
combination thereof.
Separation of Lipid and Phospholipid Classes: The separation of lipid classes
can be
performed by preparative thin-layer chromatography (TLC), for instance using
methods described
herein.
To remove any residual metal or other damaging contaminants that might be on
the TLC
plates, each plate is washed prior to use. By way of example, the following
three-step method can be
used to wash the plates: impregnate each plate with
ethylenediamine~tetraacetic acid (EDTA), then
rinse the plates once with methanol and once with chloroform. Each plate is
first impregnated with 1
mM EDTA, pH 5.5, by ascending development using the method of Ruiz and Ochoa
(J. Lipid Res.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-29-
38, 1482-1489, 1997). After each plate is completely developed, it was dried
in air overnight. Once
dry, each plate is developed in methanol, dried, and developed in chloroform,
each in the same
direction as the development with EDTA. The washed plates are then dried in
air. Just prior to use,
each plate is activated by heating it to 110 °C for 10 minutes.
To prepare the TLC chamber for chromatography, WhatmanTM (Clifton, NJ) filter
paper is
cut, for instance into 20 x 80-em strips, and wrapped around the inside wall
of a glass development
chamber (e.g., a chamber of 30 x 60 X 10-cm). An appropriate amount (e.g., 100
milliliters for the
example container) of the desired mobile phase is added to the chamber, and
the chamber sealed and
allowed to equilibrate. Chambers are generally considered equilibrated when
the solvent front has
completely ascended the filter paper.
One representative mobile phase that can be employed for the separation of
phospholipid
classes is a modification of the solvent system described by Holub and Skeaf
("Nutritional regulation
of cellular phosplzatidyliuositol," in Meth. Enzyzn., ed. Conn (Academic
Press, Inc., Orlando), pp.
234-243, 1987) consisting of chloroform/methanol/acetic acid/water
(100:67:7:4, by vol). For the
separation of neutral lipid classes (total phospholipids (PL), free fatty
acids (FFA), free sterols,
triacylglycerides (TAG), diacylglycerides, monoacylglycerides and cholesterol
esters (CE)), a solvent
system consisting of petroleum ether/diethyl ether/acetic acid (80:20:1, by
vol) can be used
(Mangold, Tlzin Layer Clzrorzzatograplzy- A Laboratory Handbook (Springer-
Verlag, New York),
1969).
After the TLC plates are cooled, sample extracts are spotted onto the
activated plate. In
certain embodiments, samples are spotted at an estimated concentration such
that no single lipid class
will be present at more than 25 pg per centimeter of plate width following
chromatography. This
helps to ensure that the plate is not overloaded and minimized the risk of
cross-contamination
between lipid classes. (Cross-contamination is readily identified during
sample analysis, particularly
were each lipid class contains at least one unique internal standard as
described herein.) Lipid class
separations are performed on TLC plates, for instance with a 10-cm separation
length, while PL class
separations are generally performed on longer TLC plates, for instance with a
20-cm separation
length.
Because lipid visualization reagents invariably degrade certain analytes, most
notably the
polyunsaturated fatty acids, the identification of individual lipid classes is
performed by comparison
with authentic lipid standards chromatographed in reference lanes. Each
reference lane is spotted
with a mixture of authentic lipid standards (obtained from Avanti Polar
Lipids, Alabaster, AL).
When the amount of sample is not limiting, the sample extract also may be
spotted onto the reference
lanes.
Once the TLC plates are spotted with samples and standards, and the tanks are
equilibrated,
the plates are transferred into the tank containing the selected mobile phase.
The samples re
chromatographed until the mobile phase ascended to 1-cm below the top of the
plate.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-30-
Once the TLC plate is developed, the reference lipids are visualized by
cutting the reference
lanes from the plate, dipping the reference lanes in 10% cupric sulfate/8%
phosphoric acid and
charring the reference lanes at 300 °C. The charred reference lanes are
used to identify the location
of lipid classes on the analytical plate. In order to preserve the
quantitative aspect of the sample
analysis, this procedure meets the following criteria: 1) reference standards
co-migrate with sample
analytes with great accuracy, regardless of the source or composition of the
analytes (for instance, see
the mirrored control and experimental chromatograms shown in Figure 4B); 2)
chromatographic
separation between the lipid classes is maximized to substantially avoid cross-
contamination; and 3)
the portion of the plate containing analytes is not exposed to environmental
stresses such as air, light
or any reagent that would cause the degradation of specific analytes.
Derivatization: Once the individual lipid classes are separated, the fatty
acids are
hydrolyzed from their respective glycerolipids and prepared for gas
chromatography. In one
particular embodiment, and merely by way of example, each lipid fraction is
scraped from the TLC
plate using a clean razor blade and placed in a 2-mL glass vial or like
container. Four-hundred
microliters (400 NL,) of 3N methanolic-HCl (Supelco, Bellafonte, PA) are added
to each vial, and the
vials are sealed under nitrogen. The sample vials are incubated at 100
°C for 45 minutes in order to
trans-methylate the fatty acids. After incubation, the vials are cooled at 4
°C for 20 minutes.
The resultant fatty acid methyl esters (FAMEs) are extracted from the
transmethylation-
mixture with hexane. For instance, and by way of example, five-hundred
microliters (500 NL) of 6%
KZC03 (w/v) and 200-p.L, of hexane, containing 0.05% butylated hydroxytoluene
or another
antioxidant, is added to each vial, and the vials are sealed and mixed on a
vortex mixer. The sample
mixture is then centrifuged at 500 x g to separate the hexane fraction, which
contains the FAMEs,
from the methanol/water fraction. The hexane containing the FAMEs is removed,
and for instance
transferred into 200-~L, conical inserts and sealed in 2-mL glass tubes under
nitrogen in preparation
for gas chromatography. Samples may be concentrated by drying under a stream
on nitrogen as
necessary.
Chromatography Fatty acid methyl esters can be separated and quantified using
known
techniques, for instance by capillary gas chromatography using a Hewlett-
Paekard (Wilmington, DE)
6890 gas chromatograph. By way of non-limiting example, analysis may be
performed using such a
gas chromatograph equipped with a 30-m DB-225MS capillary column (J&W
Scientific, Folsom,
CA), and a flame-ionization detector.
Separation conditions can be determined by one of ordinary skill in the art.
Representative
example conditions are as follows: The injector temperature is set to 270
°C and the detector
temperature set to 280 °C. The oven temperature is increased from 165
°C to 215 °C at 4.0 °C per
minute and held at 215° for 12 minutes. The temperature is then
increased to 230 °C at 30 °C per
minute and held at that temperature for three minutes to drive off any high-
boiling contaminants.
Split ratios are maintained at about 40:1.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-31-
Sterols can be separated and quantified by capillary gas chromatography using
a Hewlett-
Packard (Wilmington, DE) 6890 gas chromatograph equipped with a 30 m DB-35MS
capillary
column (J&W Scientific, Folsom, CA), and a flame-ionization detector.
Appropriate example
separation conditions are as follows: The injector temperature is set to 310
°C and the detector
temperature is set to 280 °C. The oven temperature is increased from
285 °C to 320 °C at 2.5 °C per
minute. The temperature is then increased to 335 °C at 50 °C per
minute to drive off any high-
boiling contaminants. Split ratios are maintained at about 100:1.
The column and oven conditions may be subject to slight modification over the
course of the
experiment. In particular, modifications may be necessary to ensure that every
fatty acid is
completely resolved to baseline.
Sample chromatograms generated using the above methods are shown in Figure 4.
Optionally, a sample containing known amounts of a set of standard compounds
can be run
through the analysis in like fashion, to produce a control chromatogram. Such
a control
chromatogram is shown in Figure 4B; the constituent standard compounds are
indicated.
B. Integration and Data Ha~Zdlitzg
Following chromatography, each chromatogram is integrated, for instance using
Hewlett-
Packard (Wilmington, DE) ChemStationTM software. After chromatogram
integration, the
chromatogram from each sample may be visually checked to ensure proper
integration. The resultant
data may be sent electronically to database or spreadsheet for manipulation,
for instance an Excel
2000 (Microsoft Corporation, Redmond, WA) spreadsheet. In some embodiments,
the database or
spreadsheet contains the sample identification information, quality control
algorithms, and the
algorithms required to convert the raw chromatogram data to mass or
concentration data.
Appendices I and II show a single entry in an example database for control and
test samples,
respectively. The data structure for this specific database embodiment is
discussed in more detail
below.
C. Quality Control
Several quality control protocols can be used in the described methods, to
help ensure
accurate, quantitative data from samples.
The rationally designed internal standards employed by the methods described
herein enable
true quantification of each fatty acid from each lipid class, whereas
traditional lipid analysis methods
produce data in either a percent-of total format or as a mixed population of
lipid metabolites.
Quantitative analysis of such a mixed population of lipid classes is an
analytical impossibility unless
each individual class acts essentially identically at every analytical step.
In addition to enabling each
analysis to be highly quantitative, internal standards are designed to reflect
any loss of fatty acid due
to oxidation, discrimination, or cross-contamination. The results of each
sample integration are
analyzed by an Excel 2000 macro to determine if degradation or selective loss
has occurred during
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-32-
the analysis. The macro automatically flags samples with standard profiles
deviating by more than
2% from ideal analytical results for any fatty acid of lipid class. Flagged
samples are entirely re-
analyzed.
X Integrated Metabolomic Databases
For metabolomics to develop a global knowledge base analogous to the genome
knowledge,
it is imperative that data be produced and reported in quantitative terms.
Typically in the past,
metabolite data has been reported in a percent-of total or other relational
format. Such data have
several disadvantages, including that they (1) are influenced by the number of
analytes in the tested
sample, (2) are influenced by co-variation between analytes, (3) are not
comparable between
experiments and (4) provide little basis for interpreting how metabolites
interact among themselves
and with other biomolecules. The quantitative data can be integrated from
multiple sources (whether
it is work from different labs, samples from different subjects, or merely
samples processed on
different days) into a single seamless database, regardless of the number of
metabolites measured in
each discrete analysis. Thus, abandoning rigorously quantitative methodology
in return for high-
throughput analyses would yield fragmented and non-integratable databases.
Further embodiments of the disclosure include databases of metabolomic data,
where each
database includes that metabolite quantification data from a plurality of
individual lipid metabolite
profiles. Such databases may be on a computer-readable storage medium, and may
be formatted for
processing by a computer. Data included in the databases may include any or
all of the following:
information that provides for unique identification of data from a sample;
raw quantitative measurements of individual metabolites (such as lipid
metabolites);
transformed measurements of individual metabolites (which have been subject to
one or
more mathematical transformations from raw data);
basic information about the biological sample (e.g., species, tissue,
preparation date, etc.);
genetic information about the subject from which the biological sample was
taken (e.g.,
genotype of a knockout or otherwise engineered animal);
health or care history of the subject from which the sample was taken (e.g.,
long term care
strategies, chronic conditions, etc.);
information about the treatment of the subject from which the biological
sample was taken
(e.g., drug application, feeding schedule or diet, stressors, environment, or
toxins);
information about the harvesting of the individual sample and/or the
processing of the
sample;
information about the individual Iipid metabolites (e.g., biochemical or
biological
characteristics);
information about one or more of the implicated metabolic pathways;
one or more metabolite fingerprints that are associated with a disease,
condition, treatment,
gene (or genotype), or drug application (e.g., to serve as a baseline or
control sample);
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-33-
information linking the treated or test samples to their experimental control
samples;
information about the analytical process of producing data; and/or
information about the laboratory, investigator and analytical chemists
responsible for
producing the data.
The provided databases may serve to organize metabolite information, or any of
the other
information types indicated, in one or more tables. Such tables are readily
translatable into database
languages such as SQL, and the databases optionally can be integrated with an
on-line Internet site
containing results of user-defined metabolite analyses.
According to one aspect of the present disclosure, a computer-readable storage
medium is
provided, with a relational database stored on this medium. The relational
database includes a
metabolite table, for instance containing test metabolite data, which includes
a plurality of
quantitative lipid analysis records. Each record in the table includes data
that corresponds to the level
of a lipid metabolite in the corresponding sample.
In some embodiments, the relational database includes more than one table, for
instance a
control table and a test table. In some embodiments, many tables are included,
for instance one each
for a plurality of the different types of information described above. In some
embodiments for
instance, each lipid class is separated into its own table and the column
headers for data are fatty acid
names.
In still another embodiment the data (including additional phenotypic or
biochemical data)
can be stored in many related tables, with each table representing a subset of
the data in its totality.
For example, consider an experiment in which athletes and non-athletes are
assayed for lipid
metabolite profiles and resting heart rate. One format of the resultant
database contains a table for
each lipid class assayed by the methods described herein, with columnar data
including each
individual fatty acid found in each lipid class, and may also include a
related table for phenotypic
information, in this case resting heart rate. In this example, the results
obtained from athletes and
their non-athletic controls can be stored in the same table, or in a separate
series of tables. The
preferred embodiment would allow the two groups to be stored in the same table
under unique
identifying codes such that they could be queried and identified and
discriminated as treatment and
control from a single experiment at a later date.
Filters can be defined for sorting data in the provided databases, in order to
mine the data.
Examples of filter criteria based on the types of fatty acids include the
following:
(1) Fatty Acid Family: In an embodiment using this filter, each fatty acid
family is
a filter criteria. Families may be coded by color. One representative color
scheme is as follows:
Black-"Saturated"; Maroon-"n7"; Blue- "n9"; Yellow- "Misc."; Green- "n3"; Red-
"n6"; grey-"Trans";
Light blue- "Plasmalogen";
(2) Summary Data (summarized, for instance, by lipid family, fatty acid
family,
tissue, species, etc.);
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-34-
(3) Major Fatty Acids Only: This filter displays only data from the following
Fatty
Acids: 16:0; 18:0; 16:1n7; 18:1n7; 18:1n9; 18:3n3; 20:5n3; 22:5n3; 22:6n3;
18:2n6; 18:3n6; 20:3n6;
and 20:4n6.
The database format and implementation is not essential to certain elements of
the
disclosure. It is expected that different end users will require different
systems for displaying data
that are produced by the methods described herein. For instance, a specific
requested display feature
might dictate that the database format described herein be changed. Such
modifications in database
structure are known to one of ordinary skill in the art.
By way of example, one format is described below. This format is set up for
speed
purposes, so that the application does not need to query each value separately
from the database. In
this embodiment, the following information is stored for each
control/treatment sample:
1) A unique auto-incrementing "id" field;
2) An integer value corresponding to the number of rows of data;
3) An integer value corresponding to the number of columns per row;
4) A string representing an identifier for the data (the name of the data);
and
5) The data itself, which is stored in row-major order as a comma delimited
list of values.
In this embodiment, being able to correlate two sets of data (e.g., comparing
two heart tissue
samples) is based on the labels matching. This database structure requires
only two queries to the
database before values can be computed, instead of some database formats that
require on the order
M*N queries, where M is the number of rows and N is the number of columns per
row.
The following tables (Tables 4 and 5) present MySQL descriptions for specific
embodiments:
Table 4:
mysql> describe controls;
Field T a Null Ke Default Extra
controlidint(11) PRI NULL auto increment
'
rows int(11) YES NULL
cols int(11) YES NULL
name varchar(50)YES NULL
data text ~ YES NULL
5 rows in set (U.UU see)
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-35-
Table 5:
mysql> describe treatments;
Field T a Null Ire Default Extra
treatmentidint(11) PRI NULL auto increment
rows int(11) YES NULL
cols int(11) YES NULL
name varchar(50)YES NULL
data - . text YES -.~ NULL
- ~ ~
rows in set (0.00 sec)
Certain embodiments of the provided databases contain at least two tables (for
instance, one for
controls and one for treatments), though many more tables are also
contemplated.
JCL AnalysislMizzizzg of the Database
The database can be mined by one of many standard statistical techniques. Such
techniques
may include standard difference testing between or among subsets of the data
selected by the user. In
certain embodiments, appropriate techniques include tests such as ANOVAs,
general linear models
(GLM), Student's t-tests, discriminant analyses, LOGIT models, etc. For
example, if a user wishes to
identify any specific differences in the lipid metabolites profiles of
diabetics when compared to non-
diabetics, a user may select both individuals from the database that have
diabetes and appropriate
non-diabetic controls. To identify the lipid metabolite that best
discriminates diabetics from non-
diabetics; a discriminant analysis can be performed. The results of the
discriminant analysis yield a
single metabolite and the range of biological concentrations of that
metabolite that best predicts the
presence of diabetes.
A panel or profile of metabolites that predict diabetes can be created by, for
instance, the
following two methods, (1) by performing the described analysis repeatedly,
and with each iteration,
removing the discriminated metabolite or (2) by performing a discriminant
analysis on summary or
converted data, where the input values for the discriminant analysis are
themselves values calculated
from quantitative metabolite data, computed from either a random combinatorial
approach or from a
user-defined algorithm. A user defined algorithm can be exemplified by the
following: (the sum of
all fatty acids containing a delta-5 double bond) divided by (the sum of all
fatty acids not containing a
delta-5 double bond).
The database may also be mined by visual tools, such as the "heat map" or
targeting charts
described herein, or by other methods of organizing and visualizing data
according to a user-defined
organization scheme. These methods of organization may include organizing the
data by metabolic
pathway, groupings of nutritionally related fatty acids, or the degree of
difference between or among
tested groups of samples.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-36-
I~IZ Presentation of the Data
Presentation of data from the provided databases may be, at least in part,
governed by the
goals) of the user. Thus, it is contemplated that views and user interfaces
may vary with the specific
application to which the database is being put, and the specific information
the user is mining from
the database. By way of non-limiting example, two specific models of data
output and user views are
provided. These will be referred to herein as the "heat map" model or system,
and the "targeting"
model or system.
Heat map model: A representative example of a heat map is shown in Figure 5 In
a heat
map display, quantitative metabolite data from a test sample is compared to
quantitative metabolite
data from a base line or standard sample (a control) and the increase or
decrease in each metabolite is
indicated on the display, usually in a readily recognizable visual manner.
The data points can be presented in a two-dimensional layout, such as the
chart shown in
Figure 5, so that the columns contain data from for instance individual fatty
acid chains or saturation
level, while the row are arranged by lipid class, tissue type, species, or any
combination thereof.
Other arrangements can easily be envisioned, for instance bar graphs in two or
three dimensions,
which would also enable an overall picture of the data to be displayed.
By way of example, as shown in Figure 5, the increase or decrease is indicated
on the
display by the color of the relevant block on the chart, and the relative
amount of the increase or
decrease is indicated by the intensity of that color. Thus, in the embodiment
pictured in Figure 5, an
increase in the indicated metabolite is colored green, and the brighter the
color (the further it is from
black), the greater the percentage increase. Decreases may be shown in red (of
varying intensity).
Black can be used to indicate that there is no (or relatively little) change
in the level of that
metabolite. A glance at the heat map shows clearly those columns or rows that
deviate from the
standard, because those changes are indicated in a different color.
For instance, in the data location found in the first data column of Figure 5
(labeled 14:0),
and the first row (the heart sphingomyelin (SP) sample), the test sample
contained 80% more of the
indicated metabolite (14:0 fatty acid, associated with sphingomyelin) than the
control sample; the
relevant block on the heat map is colored bright green, to indicate that the
test sample had a relatively
high increase in the level of this metabolite.
The number of gradations of color can be varied, depending on the sensitivity
desired. The
provided example displays three different intensities of red and green
Other systems than color can be used to illustrate that there is a change in
the amount of a
metabolite. For each such other system, a key is usually provided. By example,
one non-color based
system would include cross-hatching, stippling, and other "fill patterns" to
indicate increases or
decreases in metabolite level. In a three-dimensional depiction, the apparent
height of a column
(upwards or downwards from a given plain) may be indicative of the relative
amount of change in the
metabolite that is depicted by that column. One element of all of these
embodiments (including color
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-37=
coding) is that patterns of change can be recognized graphically, without
necessary recourse to raw or
processed data numbers.
Optionally, the actual percentage increase (or decrease), or the absolute
increase (or
decrease) can be indicated on the heat map. In the provided example, the
percentages are given for
those metabolites that differ from the control sample by 10% or more (Figure
5). In alternative
embodiments, the percentage can appear as a pop-up, for instance when a cursor
is passed over the
relevant location on the chart, or can be accessed by clicking on or otherwise
indicating interest in a
specific location within the chart. Relevant statistical information relating
the compared data also can
be presented in this way.
Data presented as a heat map can be organized in various ways, for instance,
by metabolic
pathway, magnitude, or direction of effect, significance of effect or by a
system of categorizing the
rarity or importance of an effect. An example of the importance of an effect
is provided in Figure 5,
which depicts many changes in lipid metabolism as the result of a
pharmaceutical intervention (see
Example 1). The increase in heart cardiolipin concentration is small relative
to the increase in many
metabolites, however, this result is rare and important to heart mitochondrial
function. One benefit of
organizing a heat map by tissue/organ or metabolic pathway is that it
facilitates identification of
systems that are strongly affected by the test condition. Similarly, other
methods of organization can
be used to highlight other information in the database.
In other embodiments, black is used to color the cells (locations in the heat
map)
representing metabolites that were not statistically different from each
other. The degree of statistical
significance required before coloring begins can be assigned by the user. In
one embodiment, a
Students t-test statistic can be calculated from the data used for comparison.
The user can determine
the level of significance required for coloring each cell. A standard level of
significance would be a
P-value of less than 0.05, which represents a 95% chance of the difference
between the average of the
treatment group and the control being truly different. If the difference
between the average of the
treatment group and the average of the control group has a P-value of less
than 0.05, then the
corresponding cell will be colored according to the degree of difference.
The user can define the "bin range" for the color scheme. For instance, one
user may want
to set a % difference of 50% to be represented by the maximum color
brightness, while another user
may wish to set the maximal difference to be 100%.
In some of the provided embodiments, the user is able to define the data type
for display.
While the database will contain quantitative data, the display type may be
quantitative data (molar),
quantitative (by mass), or relational by either moles or mass (mole % or
weight %, respectively).
These data types are easily calculated on the fly by the database engine.
The value of the differences in metabolites can be calculated in various ways,
for instance as
a percentage difference, a mean difference, or a percentage or mean difference
of transformed data
between two samples or sample groups.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-3 8-
Targeting model: A representative targeting display is shown in Figure 6. In a
targeting
display, quantitative metabolite data is compared from two samples that have
been subjected to
different treatments, for instance treatment with two different drugs or a
drug and a test compound.
The percentage or absolute changes (versus the standard sample) in the
measured metabolites are
plotted against each other on a Cartesian graph. This visual system
facilitates the comparison of the
global and individual metabolic effects of the two conditions being examined.
If the two treatments
(e.g., two drug treatments) affect the biological system in metabolically
similar ways, the data points
will fall along a line with a slope of 1, running through the origin (from the
lower left to the upper
right quadrant, in other words). Outlier data points, where one treatment or
the other has a different
effect on a metabolite, will lie in the upper left or lower right quadrants,
and are therefore easily
identified. These data points reflect a single metabolite that is increased in
one treatment, but
decreased in the other. The further off the "equivalent" slope a data point
is, the greater the
magnitude of differential effect that is being illustrated.
This format for data output is particularly useful when two conditions are
being directly
compared to each other, with only one or a very few variables are different
between the two samples.
Such conditions may be, for instance, treatment with two known drugs or
pharmaceutical agents, or
with a known drug and a toxin, unknown agent, or potential drug candidate.
Other examples include
a drug treatment compared to a genetic alteration (e.g., a knockout mutation)
or a disease state.
Representative "targeting" applications are described more fully below.
aYllZ Applications
The metabolite profiles and databases produced therefrom can be used in myriad
applications, including providing information about individual subjects, about
disease states or other
conditions, about dietary effects, about drug treatments or treatments with
drug candidates, about side
effects, and so forth. The provided methods and databases can be used to
diagnose, prognose, and/or
predict disease or other conditions, to monitor drug treatment for efficacy or
side effects, to identify
useful drug targets, to identify potential therapeutic agents with specific
metabolic effects, or to
compare the effects of multiple drugs or other compounds or conditions.
Specific examples of
individual applications are described more fully hereafter.
It is also contemplated that the lipid metabolomic methods and databases
described herein
can be used as clinical diagnostic assays, providing a comprehensive read out
of lipid metabolic
responses to a drug or drug treatment regimen. A clinician can use lipid
metabolomic profiles, taken
before, during, and after drug treatments to determine and track the
effectiveness of a drug treatment.
Metabolomic indicators of successful (or unsuccessful) treatment in many
systems are detectable
before other clinical indicators become detectable, and thus this system
provides faster and more
precise characterization of an individual's response to a treatment or
treatment regimen. Thus, a
clinician can examine lipomic data as a way to monitor the efficacy of a
particular treatment or
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-39-
dosing strategy, and adjust the treatment earlier than if conventional
laboratory indicators are used
alone.
The quantitative metabolite data, and methods for acquiring these data,
provided herein can
be used to identify and/or describe the complete metabolic consequences of
deleting, over-expressing
or otherwise changing the presence or expression of a gene. Such comparison
can be used to identify
the direct product of some genes, particularly those that are involved in the
studied metabolic
pathways (e.g., pathways of lipid catabolism or anabolism). In some
embodiments, this can be used
to identify the metabolic pathways affected or controlled by said gene. This
type of comparison also
can be used to identify what aspects of metabolism are affected by the
downstream consequences of
metabolic pathways controlled by the designated gene.
Quantitative lipid metabolome data as provided herein can be used as
quantitative traits for
gene mapping. For instance, individual fatty acid types present in single
lipid classes or aggregate
values, such as total number of moles of n-9 fatty acids per gram of plasma,
or total moles of
cardiolipin per gram of tissue, can be correlated with one or more genes. In
specific embodiments,
these quantitative traits are the products of an algorithm that relates
metabolite values to specific
genotypic changes, as the quantitative relations among metabolites are often
the result of protein gene
products.
Quantitative metabolite data, particularly quantitative lipid metabolite data
as determined
using methods described herein, can be used to identify the effects of
specific pharmaceuticals,
toxicological agents, or nutritional interventions (or combinations thereof)
on lipid metabolism.
The methods provided herein can be used to identify one or more unknown
molecular
targets of a pharmaceutical, toxin or nutrient, or the metabolic function of a
gene, by comparing the
quantitative measurements of lipid metabolites against a quantitative database
of lipid metabolites.
Such a database contains the quantitative results of trials wherein the
effects of genes,
pharmaceuticals, toxins, or nutrients are determined and recorded. One
embodiment of this approach
is depicted in Figure 5.
This disclosure includes methods for comparison of the metabolic effects of
two or more
pharmaceutical agents, genes, toxins or nutrients by comparing the
quantitative results of trials
determining the quantitative effects of these compounds on lipid metabolites.
Such quantitative
effects can be compared by directly comparing the lipid metabolite profiles of
samples that are
different as regards the agent, gene, toxin, or nutrient in question.
In some embodiments, a drug with a known mode of action is compared with a
drug
candidate whose mode of action is unknown or uncharacterized. Lipid metabolite
profile data
reflecting the effects of the known drug and the drug candidate can be plotted
against each other in a
"targeting" model output (such as shown in Figure 6). Comparison of two
treatments to each other
facilitates the identification of compounds that have similar (or dissimilar)
effects on the tested
metabolic system, and thus enables the identification of compounds that are
likely candidates as
therapeutic agents for use in specific systems.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-40-
For instance, to identify an agent that could be useful in treating diabetes,
profiles from
samples that were treated with possibly active agents (test agents) are
compared with one or more
profiles of samples that were treated with known anti-diabetes agents. Test
agents that demonstrate
similar metabolic effects to known anti-diabetes agents are identified as good
candidates for further
characterization.
Similarly, this system can be used to examine candidate agents for those that
have a similar
therapeutic effect, without one or more undesirable side effects associated
with the known therapeutic
agent. Where a known therapeutic agent is known to affect a specific
metabolite (or subset of
metabolites), a direct compound to compound metabolomic comparison (e.g.,
presented as a targeting
chart) can be used to identify agents that affect some metabolites in the same
manner as the
therapeutic agent, but that do not affect the "side effect" metabolites in the
same manner.
In specific examples of these embodiments, the biological samples are irz
vitro cultured cells
that have been subjected to treatment with different agents that are known to
or suspected of having
biological activity, and/or the characteristic of disturbing or altering the
metabolome of cells to which
they are applied.
One specific embodiment is depicted by Figure 6, wherein the percentage
difference in each
metabolite resulting from treatment is plotted for each of two treatments
trials (rosiglitazone and
CL316,243) in a two-dimensional scatter plot (a "targeting" chart). The
metabolites found in the
lower left and the upper right quadrants of the scatter plot (especially those
where the X and Y values
are similar) represent those likely affected by similar molecular mechanisms.
Metabolites present in
the upper left or the lower right quadrants of the scatter plot represent the
products of different
molecular affects of the intervention.
Other targeting chart applications include comparisons between any two
conditions, for
instance drug-toxin versus xenobiotic influence or gene-toxin versus
xenobiotic influence. This
method of data visualization can also be used, for instance, to assess the
differences caused by
individual diet component changes, or whole system dietary changes (e.g.,
omnivorous versus
vegetarian), and so forth. In essence, any two possible treatments can be
compared to each other, and
using the targeting chart the differences and similarities of metabolic
influence can be readily
determined.
Also contemplated are methods of using the provided databases to test subjects
for their
relation to a metabolic baseline, for instance prior to or following a
clinical trial. The metabolic
profile of a subject (for instance, an individual or a test animal) is
determined and compared to a base
line profile for a similar subject, or a baseline metabolic fingerprint that
has been assembled from
multiple metabolic profiles from a collection of similar subjects.
Alternatively, the metabolic profile
of the subject can be compared directly to a previous metabolic profile of
that same subject that has
been determined to be an accepted baseline for that individual subject.
Differences in the subject's
profile are indicative of deviations from the baseline.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-41-
Quantitative relationships that are defined among lipid metabolites using the
methods
described herein can be used to assess the relative activity or function of
lipid metabolic enzymes.
This approach can be used to identify protein targets of pharmaceutical
agents, genes, toxins, or
nutritional components.
Individualized risk assessment and directed metabolite analyses are also
contemplated. The
methods provided herein can be used to profile the lipid metabolites of an
individual, which results
are then compared to a database that contains a plurality of profiles from
like and similar individuals.
The individual can then be provided with, for instance, information regarding
likely health risks,
tendencies to disease or condition, appropriate (or inappropriate) diet, or
other information garnered
by comparison to the accumulated metabolomic database. In one specific
embodiment, the individual
profile is compared to subject that have been treated with specific drugs or
who have undergone other
medical treatments, and the likelihood of drug detrimental side effects for
the test individual is
determined. Individual analyses can be used to diagnose specific diseases or
conditions that affect
the metabolic system characterized by the profile and corresponding database.
Lipid metabolomics provides specific information regarding several different
diseases or
other conditions, including for instance organ transplant (e.g., likelihood of
rejection, progress of
acceptance of the donor organ), menopause (and progression through menopause),
obesity, diabetes,
cardiovascular disease, autoimmune conditions, responsiveness to drugs for
treatment of each of
these conditions (including the effectiveness of hormone therapy), and
athletic performance or
preparedness. Lipid metabolomic fingerprints can be prepared that provide
diagnostic, predictive,
and or effectiveness characteristics for each of these conditions.
IVX. Arairnal Models
The methods described herein can be used to analyze animal samples and create
an animal-
based metabolite database, such as a lipid metabolite database, that can be
mined for information.
The dominant research platform for biotechnology research is the inbred mouse.
Such mice
have constant genomes, making them particularly attractive as laboratory
research models. They
have phenotypes that mirror human diseases, and they have fixed, homozygous
genomes. Because
the genome of each inbred mouse strain is constant, and because the nutrition
of captive research
mice can be carefully controlled, phenotypic differences among strains can be
attributed directly to
differences in their genes.
The medical and pharmaceutical communities use these inbred mouse strains to
locate and
identify the genes responsible for disease and to test the efficacy of new
pharmaceutical products.
Although the locations and sequences of many disease-linked genes have been
identified, very few of
these genes have been linked with their metabolic function. Determining the
metabolic function of
genes is critical for validating the gene as a potential target for therapy.
The methods provided herein
provide the necessary link between existing genetic targets and actual
metabolic function.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-42-
Lipid metabolomic profiles are produced for each inbred mouse strain under
defined
laboratory conditions (including, for instance, feeding and watering schedule,
temperature, caging,
and so forth). Profiles can be generated for a plethora of different standard
condition sets. These
profiles then serve as a baseline to which any modification of the strain's
genome can be compared.
For instance, a knockout mouse can be generated, which has been rendered
defective in a single
target gene. By comparing the lipid metabolite profile of the knockout mouse
(or a set of such
knockout mice) under defined laboratory conditions, specific metabolic effects
of the gene knockout
can be identified. This comparison can be used to discover, test and validate
disease targets identified
through genomic-, metabolomic-, or and proteomic-based techniques.
Similarly, this comparison technique can be used to examine metabolite changes
caused by
applying a compound to the experimental mouse(or other research animal such as
monkeys), for
instance by feeding the mouse the compound. Thus, drugs and drug candidates
can quickly and
reliably be tested for their metabolic effects.
By way of example, inbred mice strains can be selected to represent a spectrum
of metabolic
disease (normal growth, obesity, lean growth, and diabetes, for instance), and
their baseline lipid
metabolite profiles assembled into a database. This database can be queried by
comparing a test lipid
metabolite profile to it, and determining the similarities and differences. An
animal database such as
the mouse database can also be used to profile the effects of specific
pharmaceutical products, for
instance products that are under public scrutiny or commercial development.
In certain embodiments of the animal lipid metabolite databases, samples are
assayed and
lipid metabolite profiles prepared from multiple tissues from each subject
mouse strain. For instance,
the database may include samples from any tissue, such as one or more than one
of the following:
blood or blood products (such as plasma), heart, adipose (all types), liver,
muscle, kidney, spleen,
lung, testes, and brain.
Examples of the provided databases also may include data from different
species, including
for instance humans, non-human primates, and mice. Comparisons of data and
data sets, as well as
trends or discrepancies in metabolite levels between data from the different
species, can provide
identification of shared or divergent pathways between the species. Comparison
of data between
different species can also be used to study or predict the effects of drugs on
the measured metabolites,
for instance in order to predict the effects of a drug in a human system after
it has been tested in an
animal model.
Other specific uses for animal model databases include drug and other
pharmaceutical
screening, hazard models (e.g., where samples are taken from animals that have
been exposed to one
or more toxins, chemicals, or other hazards), and disease testing
(particularly where there is a
recognized model animal system that is useful for gathering comparative data
that may be useful for
correlation with human disease).
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-43-
VX. External Quality Control
The metabolomic databases described herein can be used to identify biological
outliers in
incoming data. Because certain of the provided databases contain data that
defines the biological
variation in each metabolite across a wide variety of species, tissues and
conditions, the cumulative
information base can be used to identify metabolite concentrations that are
unusually high or low
given prescribed criteria. These criteria can be set by the user, and may
consist of restricting the data
used for comparison purposes to species, tissue, treatment, age, etc.
The invention is further illustrated by the following non-limiting Examples.
EXAMPLES
EXAMPLE 1: Lipid metabolome-wide effects of the peroxisome proliferator-
activated receptor Y agonist rosiglitazone
This example provides specific methods of generating and using quantified
metabolite
profiles to study the effects of a therapeutic compound.
Samples
Mouse tissue and plasma samples were a generous donation to Lipomics
Technologies from
Dr. Edward Leiter of the Jackson Laboratory (Bar Harbor, ME). Samples included
the plasma, heart,
liver and inguinal adipose of mice treated with pharmaceuticals or their
corresponding controls.
Tn trial 1, prediabetic male Fl mice (from a cross of the obese NZO and lean
NON mouse
strains) were fed a control diet with or without the presence of the PPARs-y
agonist rosiglitzazone for
4 weeks (at 0.2 g rosiglitazone per kg body weight).
In trial 2, male, inbred NZO mice were fed a control with or without the
presence of the b-3
adenergenic agonist CL316,243 for four weeks (at 0.001% CL316,243 by weight in
the dietary
chow).
In both studies, five treated and five control mice were used. Following the
treatments and
the killing of the mice, tissues and plasma were taken, chilled to -80
°C and shipped to the analysis
laboratory at Lipomics Technologies in a frozen state.
Extraction
The lipids from plasma and tissues were extracted in the presence of authentic
internal
standards by the method of Folch et al. (J. Biol. Cherrz. 226, 497-509, 1957)
by homogenization in a
fluid extractant consisting of chloroform:methanol (2:1 vol:vol). Plasma (200
ltl), or 10 mg inguinal
adipose tissue was used for each analysis. For each sample, an appropriate
mass of internal standard
was added. The internal standard compounds chosen may take many forms, but in
one specific
example the internal standards added to each plasma sample were: 1.75 pg of
heptadecanoic 1-
heptadecanoyl-2-lyso-phosphatidycholine (for lysophospholipids), 2.25
micrograms of N-
pentadecenoyl-D-erythro-sphingosylphorylcholine (for sphingomyelin), 39.93
micrograms of 1,2
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-44-
diheptadecanoylphosphatidylcholine (for phosphatidylcholine), 0.93 micrograms
of 1,2-
diheptadecenoylphosphatidylethanolamine (for phosphatidylethanolamine), 2.09
micrograms of
pentadecaenoic acid (for free fatty acids), 32.93 micrograms of
triheptadecaenoic acid (for
triacylglycerides), 27.27 micrograms of cholesteryl heptadecanoate (for
cholesterol esters) and 38.03
micrograms of stigmasterol (for free sterols).
For the analysis of liver and heart tissues, 25 mg of tissue were placed in a
ground glass
homogenizer and internal standards were added. The internal standards for use
in the analyses of
these tissues may take many forms, but in this instance consisted of: 4.75 pg
of N-pentadecenoyl-D-
erythro-sphingosylphorylcholine; 74.78 ~g of 1,2
diheptadecanoylphosphatidylcholine; 33.57 p.g of
1,2-diheptadecenoylphosphatidylserine (for phosphatidylserine); 24.13 pg of
1,2-diheptadecenoylphosphatidylethanolamine; 13.38 pg of 1,1',2,2'-
tetraheptadecaenoyl cardiolipin
(for cardiolipin); 1.12 pg of pentadecaenoic acid; 27.82 pg of
triheptadecaenoic acid; 1.56 pg of
cholesteryl heptadecanoate; and 27.70 pg of stigmasterol.
The solution mixture consisting of sample, fluid extractant, and internal
standards was
homogenized by twelve strokes with a ground-glass homogenizer. Following
homogenization, 1.8
ml of 0.01 M potassium chloride was added, and the solution was vigorously
mixed. The organic
fraction containing the lipids and the internal standards was separated from
the polar fraction of the
mixture by centrifugation. The lipid extract was removed from the mixture and
concentrated under a
stream of nitrogen in preparation for lipid class separation.
Separation of Lipid and Phospholipid Classes
The separation of lipid classes was performed by preparative thin-layer
chromatography
(TLC), essentially as previously described (Watkins et al., Lipids 36:247-254,
2001). To remove any
residual metal or other damaging contaminants on the TLC plates, each plate
was washed prior to
use. Washing the plates is a three-step process that involves impregnating
each plate with
ethylenediamine tetraacetic acid (EDTA) and rinsing the plates once with
methanol and once with
chloroform. Each plate is first impregnated with 1 mM EDTA, pH 5.5, by
ascending development
using the method of Ruiz (J. Lipid Res. 38, 1482-1489, 1997). After each plate
was completely
developed, it was dried in air overnight. Once dry, each plate was developed
in methanol, dried, and
developed in chloroform in the same direction as the development with EDTA.
The washed plates
were then dried in air. Just prior to use, each plate was activated by heating
to 110 °C for 10 minutes.
To prepare the TLC chamber for chromatography, Whatman (Clifton, NJ) filter
paper was
cut into 20 ~c 80-cm strips and wrapped around the inside wall of a 30 x 60 x
10-cm glass
development chamber. One hundred milliliters of the appropriate mobile phase
was added to the
chamber, and the chambers were sealed and allowed to equilibrate. Chambers
were considered
equilibrated when the solvent front had completely ascended the filter paper.
The mobile phase
employed for the separation of phospholipid classes (lyso-phospholipids,
sphingomyelin,
phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and
cardiolipin) was a
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-45-
modification of the solvent system described by Holub and Skeaf ("Nutritional
regulation of cellular
phosphatidylinositol," in Meth. Enzyrn., ed. Conn (Academic Press, Inc.,
Orlando), pp. 234-243,
1987) consisting of chloroform/methanol/acetic acid/water (100:67:7:4, by
vol).
For the separation of neutral lipid classes (free fatty acids, free sterols,
triacylglycerides and
cholesterol esters), a solvent system consisting of petroleum ether/diethyl
ether/acetic acid (80:20:1,
by vol) was used (Mangold, Thin Layer Claronaatograplay- A Laboratory Handbook
(Springer-Verlag,
New York), 1969).
After the TLC plate was activated, the sample extracts were spotted onto the
activated plate.
As a general rule, samples were spotted at an estimated concentration such
that no single lipid class
was present at more than 25 pg per centimeter of plate width following
chromatography. This
ensured that the plate was not overloaded and minimized the risk of cross-
contamination between
lipid classes (cross-contamination is readily identified during sample
analysis as each lipid class
contains unique internal standards). Authentic lipid class standard compounds
were spotted on the
two outside lanes of the thin-layer chromatography plate to enable
localization of the sample lipid
classes.
Lipid class separations were performed on TLC plates with a 10-cm separation
length, while
PL class separations were performed on TLC plates with a 20-cm separation
length. Because lipid
visualization reagents invariably degrade certain analytes, most notably the
polyunsaturated fatty
acids, the identification of individual lipid classes was performed by
comparison with authentic lipid
standards chromatographed in reference lanes. Each reference lane was spotted
with a mixture of
authentic lipid standards (obtained from Avanti Polar Lipids, Alabaster, AL),
and when the amount of
sample is not limiting, the sample extract was also spotted onto the reference
lanes. Once the TLC
plates were spotted and the tanks were equilibrated, the plates were
transferred into the tank
containing the appropriate mobile phase, and the sample was chromatographed
until the mobile phase
ascended to 1-cm below the top of the plate.
Once the TLC plate is developed, the reference lipids were visualized by
cutting the
reference lanes from the plate, dipping the reference lanes in 10% cupric
sulfate/8% phosphoric acid
and charring the reference lanes at 300 °C. The charred reference lanes
were used to identify the
location of lipid classes on the analytical plate. Each sample was scraped
from the plate using a clean
razor blade and the silica scrapings were placed in a 2-mL glass vial for
derivitization. Great care
was taken to develop this process so that it meets the following criteria:
(1) reference standards co-migrate with sample analytes with great accuracy;
(2) chromatographic separation between the lipid classes is maximized to avoid
any
cross-contamination problems; and
(3) the portion of the plate containing analytes is not exposed to
environmental stresses such
as air, light or any reagent that would cause the degradation of specific
analytes.
The silica scrapings containing the free sterol fraction were exposed to a
fluid extractant
consisting of one milliliter of chloroform:methanol (2:1 vol/vol). The mixture
was mixed vigorously
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-46-
and allowed to sit for 15 minutes, then 0.3 mL of 0.01 M potassium chloride
was added, and the
solution once again mixed vigorously. The organic fraction containing free
sterols was separated
from the polar fraction of the mixture by centrifugation. The extract
including free sterols was
removed from the mixture and completely dried down under a stream of nitrogen.
A 20-~L aliquot of
chloroform was used to transfer the reconstituted free sterols to a conical
insert in preparation for free
sterol separation via capillary gas chromatography. No derivitization was
necessary to prepare the
free sterols for gas chromatographic analysis.
Derivatization
Once the individual lipid classes were separated, the fatty acids were
hydrolyzed from their
respective glycerolipids and prepared for gas chromatography. Each lipid
fraction was scraped from
the TLC plate using a clean razor blade and placed in a 2-mL glass vial. A 400-
pL, aliquot of 3N
methanolic-HCl (Supelco, Bellafonte, PA) was added to each vial, and the vials
were sealed under
nitrogen. The sample vials were incubated at 100 °C for 45 minutes in
order to trans-methylate the
fatty acids. After incubation, the vials were cooled at 4 °C for 20
minutes. The fatty acid methyl
esters were extracted from the transmethylation-mixture with hexane. A 500-pI,
aliquot of 6%
I~ZC03 (w/v) and 200 l.tL of hexane containing 0.05%o butylated hydroxytoluene
as an antioxidant
was added to each vial, and the vials were sealed and mixed on a vortex mixer.
The sample mixture
was then centrifuged at 500 x g to separate the hexane fraction, which
contained the fatty acid methyl
esters, from the methanol/water fraction. The hexane containing the fatty acid
methyl esters was
transferred into 200-pI, conical inserts and sealed in 2-mL glass tubes under
nitrogen in preparation
for gas chromatography. Each sample was concentrated by drying the sample
under a stream on
nitrogen as necessary.
Chromatography
Fatty acid methyl esters were separated and quantified by capillary gas
chromatography
using a Hewlett-Packard (Wilmington, DE) 6890 gas chromatograph equipped with
a 30 m DB-
225MS capillary column (JAW Scientific, Folsom, CA), and a flame-ionization
detector, essentially
as previously described (Watkins et al., Lipids 36: 247-2548, 2001). The
separation conditions were
as follows: The injector temperature was set to 270 °C and the detector
temperature will be set to
280 °C. The oven temperature was increased from 165 °C to 215
°C at 4.0 °C per minute and held at
215 °C for 12 minutes. The temperature was then increased to 230
°C at 30 °C per minute and held at
that temperature for three minutes to drive off any high-boiling contaminants.
Split ratios were
maintained at about 40:1. The column and oven conditions described above are
subject to slight
modification over the course of the experiment because this laboratory
requires that every fatty acid
be completely resolved to baseline for a chromatogram to pass quality control.
A sample
chromatogram is provided in Figure 4A.
Sterols were separated and quantified by capillary gas chromatography using a
Hewlett-
Packard (Wilmington, DE) 6890 gas chromatograph equipped with a 30 m DB-35MS
capillary
column (J&W Scientific, Folsom, CA), and a flame-ionization detector. The
separation conditions
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-47-
were as follows: The injector temperature was set to 310 °C and the
detector temperature was set to
280 °C. The oven temperature was increased from 285 °C to 320
°C at 2.5 °C per minute. The
temperature was then increased to 335 °C at 50 °C per minute to
drive off any high-boiling
contaminants. Split ratios were maintained at about 100:1. The column and oven
conditions
described above were subject to slight modification over the course of the
experiment because this
laboratory requires that every sterol be completely resolved to baseline for a
chromatogram to pass
quality control.
Integration, Data Handling and Visualization
Following chromatography, each chromatogram was integrated using Hewlett-
Packard
(Wilmington, DE) ChemStationTM software. At the beginning of each batch of
samples, a standard
mixture was run, containing a known concentration of each of the fatty acids
listed in Table 6, below.
Each fatty acid in its methyl ester form is present in this standard mixture.
The quantitative standard
was used to set a calibration table that automatically corrected the areas
associated with each fatty
acid methyl ester from the samples for injection discrimination and injector
non-linearity. A
representative chromatogram from a standard mixture is shown in the bottom
half of Figure 4B.
Significant differences were assigned to a difference in a lipid metabolite
concentration
between treated and control mice on the basis of Student's t-tests (P< 0.05).
Quantitative (nmol per g) data were visualized using the Lipomics SurveyorTM
software
system, which creates a "heat-map" graph (Figure 5) of the difference between
the data for treated
and control mice. The SurveyorTM data are read as follows: the column headers
display the fatty acid
and the family of fatty acids present in each lipid class, which are in turn
described in the row
headers. The lipid classes are grouped by tissue, and color-coded by metabolic
pathway, as depicted
in Figure 5. The heat map displays an increase in each metabolite in
rosiglitazone-treated mice
relative to control mice as a green square and a decrease in a metabolite as a
red square. The
brightness of the square indicates the magnitude of the difference, as
detailed in the figure legends.
RESULTS:
Metabolomic assessment of plasma lipids
The results of the quantitative assessment of the plasma lipid metabolome in
rosiglitazone-
treated and untreated mice are shown in Figures 7 and 5. Lipid metabolite
concentrations in plasma
confirmed the rosiglitazone-induced depletion of specific classes of plasma
lipids. Significant
rosiglitazone-mediated decreases in phosphatidylcholine, triacylglyceride, and
cholesterol ester
distinguished rosiglitazone-treated mice from untreated mice, whereas no
significant decreases in
sphingomyelin, phosphatidylethanolamine, or free fatty acids were observed
(Figure 7).
Phosphatidylcholine, cholesterol ester, and triacylglycerides are derived
principally from liver lipid
export. Total plasma triacylglyceride concentrations were lower in treated
mice (400 nmol/g) than in
untreated mice (1,400 nmol/g) (Figure 7). The concentrations of total plasma
free fatty acids, which
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-48-
are derived principally from adipose tissue, were not affected by
rosiglitazone treatment. Although
the total concentrations of phosphatidylcholine and cholesterol ester were
lower in rosiglitazone-
treated mice than in untreated mice, the absolute concentration of palmitoleic
acid (16:1n7) within
these lipid classes and within free fatty acids was higher in treated mice
than in controls (Figure 5).
The increased palmitoleic acid concentrations in plasma were reflective of the
increased de novo
lipogenesis occurring within the liver and adipose tissue (see below). .
Induction of de novo lipogenesis
Rosiglitazone-treated mice showed clear signs of increased de novo lipogenesis
relative to
control mice. Every lipid class in liver except sphingomyelin and the free
fatty acid, cholesterol ester
and total phospholipids of plasma contained a quantitative increase in
palmitoleic acid (16:1n7).
Additionally, the free fatty acid and triacylglycerides in adipose and every
phospholipid class in heart
contained an increased concentration of 16:1n7. 16:1n7 is the direct
biosynthetic product of fatty
acid synthase (the metabolic pathway for producing fatty acids in vivo) and
the 49 desaturase.
Additionally, this fatty acid was not present in the experimental diet. Hence,
the substantial increase
in 16:1n7 present in many liver, plasma, heart and adipose lipid classes (see
Figure 5, column header
"16:1n7") is the direct product of de novo lipogenesis.
The bright green cross-hatch pattern (horizontal- "liver TAG"; vertical-
"16:1n7") combined
with the clear depletion of triacylglycerides from plasma (bright red line
next to "plasma TAG")
visible in the "heat map" produced from the data (Figure 5) from this study
suggests a dual cause for
the known accumulation of lipid in the livers of rosiglitazone-treated mice.
First, it is clear that the
rosiglitazone treatment caused a decrease in triacylglyceride mobilization
from the liver into plasma.
This result is confirmed by data acquired by Dr. Edward Leiter of the Jackson
Laboratory, which
demonstrated an increase in the expression of genes involved in the retention
of lipid by the liver.
Second, the increased liver lipid content resulting from the lack of
triacylglyceride mobilization is
compounded by an increased de rZOVO synthesis of lipid as described above.
Liver lipid metabolism
The results of the quantitative assessment of the liver lipid metabolome in
rosiglitazone-
treated and untreated mice are shown in Figures 7 and 5. Lipid metabolites in
the liver demonstrated
a reciprocal relation between liver and plasma lipid concentrations. The
significant rosiglitazone-
mediated decreases in plasma triacylglycerides were balanced by a substantial
accumulation of
triacylglycerides within the liver (Figures 7 and 5). Total hepatic
triacylglycerides were 81,300
nmol/g in untreated mice and 150,400 nmol/g in the rosiglitazone-treated mice.
The concentrations
of other lipid classes were not affected by rosiglitazone treatment with the
exception of
sphingomyelin, which was present at 1,180 nmol/g in treated mice and at 1,890
nmol/g in untreated
control mice (Figure 7). This rosiglitazone-induced reciprocity between liver
and plasma
triacylglycerides is consistent with an inhibition of normal liver-plasma
lipid exchange. No change
was observed in the total concentration of phosphatidylcholine or cholesterol
ester in liver as a
consequence of rosiglitazone treatment (Figure 7).
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-49-
Inhibition of peroxisomal lipid metabolism
Two major types of lipids quantified in this study are derived from
biosynthetic pathways
present in the peroxisome. The fatty acids with three double bonds on the
carboxylic acid side of an
n-9 double bond (22:5n6 and 22:6n3) are synthesized by retroconversion from
their biosynthetic
precursors (24:5n6 and 24:6n3, respectively) in the peroxisome. The
plasmalogen lipids, those lipids
that contain one or more 1-enyl-ether-linked fatty acids, are also derived
from biosynthetic pathways
present in the peroxisome. In hearts from mice treated with rosiglitazone
there was a substantial
decrease in the 22:6n3 content of all phospholipid classes except
sphingomyelin, as well as in free
fatty acids and cholesterol esters, relative to control mice. Additionally,
there was a significant
depletion of 1-enyl-ether linked fatty acids from the heart phospholipids of
rosiglitazone-treated mice
relative to control mice. These observations are easily detectable in Figure
5, which portrays this data
in the described "heat map" format. Each of these observations suggests that
rosiglitazone, a known
PPARs-~( agonist, has an inhibitory effect on lipid synthesis in the
peroxisome.
Heart lipid class metabolism
The results of the quantitative assessment of the heart lipid metabolome in
rosiglitazone-
treated and untreated mice are shown in Figures 7 and 5. Free fatty acids are
the primary source of
energy for the heart. The average concentration of total free fatty acids in
the heart was 5,100
nmol/gin untreated mice and 2,500 nmol/g in rosiglitazone-treated mice (Figure
7). This difference
was largely independent of the type of free fatty acid, as the saturated n-3,
n-6, and n-9 families of
fatty acids were all approximately 50% lower in treated mice than in untreated
mice (Figure 7). The
free n-7 fatty acids were not depleted as substantially from heart, likely due
to the increased
biosynthesis of n-7 fatty acids and corresponding increased concentration of n-
7 fatty acids within the
triacylglycerides and free fatty acids of plasma.
The hearts of rosiglitazone-treated mice were significantly enriched with
cardiolipin, the
primary structural lipid of the inner mitochondrial membrane. The mean
cardiolipin content of hearts
from rosiglitazone-treated mice was 3,000 nmol/g as compared with 2,500 nmol/g
in untreated mice.
Unlike free fatty acids, the fatty acid components of cardiolipin were
differentially modulated by
rosiglitazone treatment. The primary fatty acid of cardiolipin, linoleic acid
(18:2n6), was 4,550
nmol/g in control heart cardiolipin and 8,850 nmol/g in heart cardiolipin of
rosiglitazone-treated
mice. Docosahexaenoic acid (22:6n3) was depleted from cardiolipin in the
hearts of treated mice
(950 nmol/g) relative to hearts of control mice (2,200 nmol/g).
The plasmalogen lipids, those lipids that contain 1-enyl-ether-linked alkyl
chains, are
derived from the dihydroxyacetone phosphate pathway and are partially
synthesized within the
peroxisome. The concentration of plasmalogens was lower in the heart
phospholipids of mice treated
with rosiglitazone than of controls (Figure 5). These data are consistent with
a decreased peroxisomal
synthesis of lipids within the hearts of treated mice.
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-50-
Adipose lipid class metabolism
The results of the quantitative assessment of the inguinal adipose lipid
metabolome in
rosiglitazone-treated and untreated mice are shown in Figures 7 and 5.
Inguinal fat tissue from
rosiglitazone-treated mice displayed a 5.7% lower triacylglyceride content
(9,628 ~mol/g) than
inguinal adipose from controls (1,019 pmol/g), and 35% more free fatty acids
(13,370 mnol/g in
treated mice and 9,900 nmol/g in controls). No significant differences in
total phosphalipid or
cholesterol ester concentrations were observed (Figure 7).
The fatty acid composition of inguinal fat triacylglycerides was substantially
altered by
rosiglitazone treatment, with inguinal fat from treated mice accumulating
fatty acids from the
saturated n-7 and n-3 families of fatty acids, while being depleted of the n-9
family of fatty acids
(Figure 7). In particular, an unusual accumulation of n-3 fatty acids was
observed in inguinal fat
from rosiglitazone-treated animals. The concentration of total n-3 fatty acids
in the inguinal fat
triacylglycerides of treated mice was 71,260 nmol/g, representing a 120%
greater concentration than
that in untreated mice (Figure 7). The most notable increases within the n-3
family of fatty acids
were a 522% greater concentration (4,100 nmol/g) of eicosapentaenoic acid, a
612% greater
concentration (7,000 nmol/g) of docosahexaenoic acid, and 84% (24,300 nmol/g)
more a-linolenic
acid in inguinal fat triacylglycerides in treated as compared with control
mice (Figure 5). The
concentration of n-7 fatty acids in inguinal fat triacylglycerides was 303
~mol/g in treated mice and
204 ~mol/g in untreated controls (Figure 7). In contrast, the total
concentration of n-6 fatty acids was
less than 3% higher. However, the accumulation or depletion of individual
fatty acids within the n-6
family varied substantially. Whereas linoleic acid (18:2n6), by far the most
prominent n-6 fatty acid
in inguinal fat, was not significantly altered by treatment, the
concentrations of y-linolenic, dihomo-y-
linolenic, and arachidonic acids in inguinal fat were respectively, 1,225
nmol/g (78 %), 1,300 nmol/g
(64 %), and 3,800 nmol/g (276 %) greater in treated mice than in untreated
controls (Figure 5).
The concentration of plasmalogen lipids in inguinal fat phospholipids was
depleted by
rosiglitazone treatment (Figure 7). The concentration of total plasmalogen
fatty acids from the
phospholipids of inguinal fat was 130 nmol/g (60%) less in treated mice than
untreated controls.
Differential effects on individual organs
It is clear from Figure 5 that the effect of rosiglitazone is variable on
different tissues, and
that a complete metabolomic assessment, including the measurement of both
fatty acids and lipid
classes from several tissues is important for understanding the true effects
of rosiglitazone on lipid
metabolism.
Comparison of the results from trial 1 and trial 2.
CL316,243 is a (3-adenergenic receptor agonist that is also used to lower
plasma glucose
concentrations in diabetic model systems. The effect of CL316,243 on plasma
total triacylglycerides
is known to be similar to that of rosiglitazone. The similarity of effect
between these two compounds
on plasma lipids is largely validated by lipomic analysis results. This can be
observed visually when
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-51-
the quantitative results from a complete metabolomic assessment of both
rosiglitazone and
CL316,243 are plotted together in a "targeting" graph (Figure 6).
However, there a several metabolites that cluster in the upper Ieft quadrant
of the targeting
graph, including cholesterol ester 16:1n7, triacylglyceride 16:1n7,
cholesterol ester 18:1n7,
phosphatidylcholine 16:17 and cholesterol ester 20:3n9. Each of these fatty
acids can be produced de
fzovo in animals, and none of these fatty acids were prevalent in the
experimental diet. Hence, the
cluster of metabolites present in the upper left quadrant of the targeting
graph clearly show an
increase in the de novo synthesis of fatty acids resulting from rosiglitazone
treatment, and that this
increase was not induced by CL316,243. These results are consistent with the
lipomic findings in
liver (discussed above), and demonstrate the utility of a targeting graph for
identifying the differences
in metabolic response to two individual affectors.
Discussion
Rosiglitazone treatment is often accompanied by weight gain in humans, an
effect strikingly
reflected by the rosiglitazone-induced increase in body weight of already
markedly-obese (NZO x
NON)Fl male mice. In this study, the potent anti-hyperglycemic effect of
rosiglitazone was
accompanied by an increased de novo synthesis of fatty acids. Palmitoleic acid
(16:1n7) and
vaccenic acid (18:1n7) were excellent metabolic indicators of the increased de
novo synthesis of fatty
acids, and the effect appeared to be mediated by an increased expression of
fatty acid synthase within
in the liver. This increased synthesis of fatty acids is likely a key
metabolic explanation for both the
weight gain and the severe hepatic steatosis observed in the rosiglitazone-
treated animals.
Interestingly, although lipid biosynthesis was increased, the increase in
liver triacylglyceride
concentration was not reflected in the plasma. Thus, there is a strong
indication that normal lipid
import-export activities between the liver and plasma were impaired by
rosiglitazone treatment, and
that this dysregulation and increased biosynthesis of lipids may be mutually
responsible for the
hepatic steatosis.
Because rosiglitazone decreased the concentrations of plasma lipids as classes
of molecules
(i.e., triacylglycerides, cholesterol esters, etc.), standard clinical markers
of lipid metabolism did not
reflect the increased hepatic de zzovo lipogenesis in response to
rosiglitazone treatment. In contrast,
the metabolomic assessment of plasma lipids identified several markers of
increased liver
lipogenesis, including an increased absolute concentration of I6:1n7 and
l8:In7 in plasma
cholesteryl esters, phosphatidylcholine, and triacylglycerides, despite the
decrease in the
concentration of total plasma lipid classes. The metabolomic analysis of the
plasma alone was
therefore capable of making the important discrimination between hypolipidemia
caused by
decreased lipid synthesis compared with hypolipidemia caused by impaired
export of lipid by the
liver. These data suggest that metabolomic analyses of human plasma have
strong potential as
clinical diagnostics. Further demonstrating the strong relations between the
plasma lipid metabolome
and tissue metabolism were the decreased concentration of plasmalogen lipids
in plasma and the
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-52-
similarity between the composition of the plasma lipid metabolome and liver
and adipose
metabolomes.
Heart lipid metabolism was strongly influenced by rosiglitazone treatment. In
particular,
heart free fatty acids, cardiolipin, plasmalogen lipids, and the important
polyunsaturated fatty acids
22:6n3 and 18:2n6 were significantly modulated by treatment. Some of these
changes, particularly
those involving the concentration and composition of cardiolipin and free
fatty acids, may in part
represent the alterations in muscle metabolism that improve insulin
sensitivity. Cardiolipin is an
essential phospholipid for energy metabolism and the primary phospholipid of
the inner
mitochondria) membrane. The content and composition of cardiolipin are
important to the efficiency
of electron transport. Rosiglitazone caused an increase in heart cardiolipin
concentration and a
substantial remodeling of cardiolipin toward an elevated 18:2n6 content and a
diminished 22:6n3
content. Interestingly, this is precisely the change in cardiolipin content
and composition that would
increase electron transport efficiency and decrease electron leakage,
according to the existing izz vitro
data. Rosiglitazone-induced remission from hyperglycemia in combination with
reduced plasma
insulin concentrations indicated that glucose oxidation by tissues was
increased by this insulin-
sensitizing agent. Thus, it is possible that increased energy metabolism as
well as decreased plasma
lipids may have caused the decreased heart free fatty acid concentrations.
Two major types of lipids quantified in this study are synthesized at least in
part, within the
peroxisome. These are the fatty acids with three double bonds on the
carboxylic acid side of an n9
double bond (22:5n6 and 22:6n3) (Moore et al., J. Lipid Res., 36:2433-2443,
1995; Sprecher et al., J.
Lipid Res., 36:2471-2477, 1995; Voss et al., J. Biol. Clzezn. 266:19995-20000,
1991), and the
plasmalogen lipids, which are synthesized by the dihydroxyacetone phosphate
biosynthetic pathway
~ (Nagan & Zoeller, Prob. izz Lipid Res., 40:199-229, 2001). Heart tissue from
rosiglitazone-treated
mice contained significantly less 22:6n3 in phosphatidylcholine,
phosphatidylethanolamine,
cardiolipin, phosphatidylserine/inositol, free fatty acids, and cholesterol
esters than did heart from
untreated control mice,. Additionally, there was a significant depletion of
plasmalogen lipids from the
heart phospholipids of treated mice relative to untreated controls. These
observations suggest that
rosiglitazone, a known PPARy agonist, has an inhibitory effect on lipid
biosynthesis in the
peroxisome. The decreased production of 22:6n3 and plasmalogen lipid may have
important
physiologic consequences. Dietary 22:6n3 has well-documented positive effects
on cardiac function,
and plasmalogen lipids have recently been shown to be essential to membrane
trafficking and the
structure of caveolae, clathrin-coated pits, endoplasmic reticulum, and Golgi
cisternae.
A curious fording in this study was the inguinal fat tissue accumulation of
polyunsaturated
fatty acids in response to rosiglitazone. Accumulation of 22:6n3 and other
long-chain
polyunsaturated fatty acids likely occurs via a pathway independent of their
biosynthesis de zzovo
from precursors. The conversion of polyunsaturated-rich phospholipids to
triacylglycerides via a
phospholipase D pathway also does not appear to be the primary metabolic basis
for the enrichment
with polyunsaturates, as phospholipids were also enriched with polyunsaturated
fatty acids. This
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-53-
unusual response may be an important clue to understanding the physiology of
adipose tissue
activated by PPARy agonists, and should be investigated further.
The present study utilized a diabetic mouse model in which the anti-diabetic
action of a TZD
was accompanied by excessive weight gain and major alterations in the lipid
metabolome. Its major
findings were that rosiglitazone (i) induced hypolipidemia by disrupting the
mobilization of liver
lipids into plasma, (ii) induced de zzovo fatty acid synthesis, (iii)
diminished the biosynthesis of lipid
synthesized within the peroxisome, (iv) had substantial effects on heart
cardiolipin and free fatty acid
metabolism, and (v) exerted tissue-specific effects on lipid metabolism.
The results presented above clearly demonstrate that metabolomic data can be
obtained,
stored, visualized, and analyzed using methods provided herein.
EXAMPLE 2: Disease/Condition-Linked Lipid Metabolite Profiles (Fingerprints)
With the provision herein of methods for determining the quantitative levels
of a
comprehensive panel of lipid metabolites, and the ability to assemble such
individual metabolite
profiles into a minable database, disease- or condition-linked lipid
metabolite profiles (which provide
information on the disease or condition state of a subject) are now enabled.
Disease or condition linked lipid metabolite profiles comprise the distinct
and identifiable
pattern of levels of lipid metabolites, for instance a pattern of high and low
levels of a defined set of
metabolites or subset of like or unlike metabolites, or molecules that can be
correlated to such
metabolites (such as biosynthetic or degradative enzymes that affect such
metabolites). The set of
molecules in a particular profile usually will include at least one of those
listed in Table 6.
Table 6:
SCIENTIFIC NAME SCIENTIFICOMMON NAME
C ABBR.
- S A T U R A T E
D -
Tetradecanoic Acid 14:0 Myristic Acid
Pentadecanoic Acid 15:0 -
Hexadecanoic Aeid 16:0 Palmitic Acid
Heptadecanoic Acid 17:0 Margaric Acid
-
Octadecanoic Acid 18:0 Stearic Acid
Eicosanoic Acid 20:0 Arachidic Acid
Docosanoic Acid 22:0 Behenic Acid
Tetracosanoic Acid 24:0 Li noceric Acid
- D9 DESATURASE FAMILY
-
9-Tetradecenoic Acid 14:1n5 Myristoleic Acid
9-Hexadecenoic Acid 16:1n7 Palmitoleic Acid
11-Octadecenoic Acid 18:1n7 Vaccenic Acid
9-Octadecenoic Acid 18:1n9 Oleic Acid
11-Eicosenoic Acid 20:1n9 Eicosenoic Acid
5,8,11-Eicosatrienoic20:3n9 Mead Acid
Acid
13-Docosenoic Acid 22:1n9 Erucic Acid
15-Tetracosenoic Acid24:1n9 Nervonic Acid
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-54-
Table 6 (cuzzt.):
SCIENTIFIC NAME SCIENTIFI COMMON NAME
C ABBR.
- OMEGA 3 FAMILY -
9,12,15-Octadecatrienoic18:3n3 a-Linolenic Acid
Acid
6,9,12,15-Octadecatetraenoic18:4n3 -
Acid
11,14,17-Eicosatrienoic20:3n3 Eicosatrienoic
Acid Acid (ETA)
8,11,14,17-Eicosictetraenoie20:4n3
Acid
5,8,11,14,17-Eicosapentaenoic20:5n3 Eicosapentaenoic
Acid Acid (EPA)
7,10,13,16,19-Docosapentaenoic22:5n3 Docosapentaenoic
Acid Acid
(DPA)
4,7,10,13,16,19-Docosahexaenoic22:6n3 Docosahexaenoic
Acid Acid (DHA)
6,9,12,15,18,21-Tetracoshexaenoic24:6n3 Tetracosahexaenoic
Acid
Acid
- OMEGA 6 FAMILY -
9,12-Octadecadienoic 18:2n6 Linoleic Acid
Acid
6,9,12-Octadecatrienoic18:3n6 g-Linolenic Acid
Acid
11,14-Eicosadienoic 20:2n6 Eicosadienoic Acid
Acid
8,11,14-Eicosatrienoic 20:3n6 Homo-g-Linolenic
Acid Acid
5,8,11,14-Eicosicatetraenoic20:4n6 Arachidonic Acid
Acid
13,16-Docsadienoic Acid22:2n6 Docosadienoic Aeid
7,10,13,16-Docosicatetraenoic22:4n6 Docosicatetraenoic
Acid Acid
4,7,10,13,16-Docosa 22:5n6 Docosa entaenoic
entaenoic Acid Acid
- UNUSUAL FAMEs -
9-Trans-Hexadecenoic tl6:ln7 Palmitelaidic Acid
Acid
9-Trans-Octadecenoic tl8:ln9 Elaidic Acid
Acid
8-Eicosaenoic Acid 20:1n12 -
5-Eicosaenoic Acid 20:1n15 -
Plasmalogen fatty acids16:0 -
" 18:0 -
" 18:1n7 -
l8:1n9 -
-STEROLS-
5b-cholestan-3b-of CZ~H480 coprostanol
5a-cholestan-3b-of Cz~H480 dihydrocholesterol
5-cholesten-3b-of CZ~H460 cholesterol
5,24-cholestadien-3b-ofCZ~H440 desmosterol
5-cholestan-25a-methyl-3b-ofCZ8H4z0 campesterol
5-cholestan-24b-methyl-3b-ofCZSH420 dihydrobrassicasterol
5-cholesten-24b-ethyl-3b-ofCZ~HSOO
b-sitosterol
5,22-cholestadien-24b-ethyl-3b-ofCz9H480 stigmasterol
By way of example, any subset of the metabolites listed in Table 6 may be
included in a
single lipid metabolite profile. Specific examples of such subsets include
those metabolites (1) that
are linked by a biosynthetic or biodegradative pathway, (2) that are
precursors or products of each
other, and so forth. Alternatively, some subsets include those metabolites
that show an increasing
level during progression of a disease or condition such as diabetes, obesity,
heart disease, coronary
artery disease, liver disease, menopause, pregnancy, or hyper- or
hypothyroidism; those that show a
decreasing level; those that are most highly correlated to a particular stage
or progression of a
specified disease or condition, and so forth. Alternatively, lipid metabolite
profiles may be further
broken down by the tissue from which metabolites were harvested for the
profile. Thus, certain
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-55-
examples of profiles may include a specific class of lipid metabolites that
are found only in, or are
found only to be affected in, a specific tissue, such as heart, nerve (such as
brain), liver, adipose,
connective, or other tissue. In some instances, selection of such tissue-
specific profiles may be
guided by existing knowledge that that tissue (or those tissues) is involved
in the disease or condition
under study.
Particular metabolite profiles are specific for a particular stage of normal
tissue (e.g., normal
heart tissue), a particular nutritional state (e.g., growth on a particular
diet), a particular condition or
disease (e.g., diabetes), or a disease or condition progression (e.g.,
progression of menopause, for
instance as a set of profiles from a single subject over a period of time
prior to, during, and after onset
of menopause). Each profile includes information on the level of a set of
lipid metabolites that are
linked to the disease or condition being studied (e.g., menopause-progression
linked metabolites).
Such information usually includes absolute levels of specific metabolites, and
may similarly include
the levels of a class (or classes) of metabolites that are linked by a
biochemical pathway, or
metabolites that are otherwise biochemically related to each other. Results
from the lipid metabolite
profiles of an individual subject are often viewed in the context of a test
sample compared to a
baseline or control sample profile, or a known profile compiled from a
database of individual
profiles.
The levels of lipid metabolites that make up a lipid metabolite profile can be
measured in
any of various known ways, including specifically those methods described
herein. In particular, it is
contemplated that any method that can be used to generate a quantitative
measurement of individual
metabolites, particularly a chromatographic method, can be used to generate
data for use in the
described lipid metabolite profiles.
EXAMPLE 3: Identification of Compounds
The linkage of specific lipid metabolites, or sets of lipid metabolites, and
the levels thereof
(for instance, as shown in a lipid metabolite profile), to a disease,
condition, or predilection of an
individual to suffer from or progress in a disease or condition, can be used
to identify compounds that
are useful in treating, reducing, or preventing that disease or condition, or
development or
progression of the disease or condition.
By way of example, a test compound is applied to a cell, for instance a test
cell, and a lipid
metabolite profile is generated and compared to the equivalent measurements
from a test cell that was
not so treated (or from the same cell prior to application of the test
compound). Similarly, in some
embodiments, the test compound is applied to a test organism, such as a mouse.
If application of the
compound alters levels) of one or more lipid metabolites (for instance by
increasing or decreasing
that level), or changes the lipid metabolite profile, then that compound is
selected as a candidate for
further characterization.
Control lipid metabolite profiles useful for comparison in such methods may be
constructed
from, for instance, normal tissue or cells, tissue or cells taken from a
subject known to suffer from the
CA 02452660 2003-12-31
WO 03/005628 PCT/US02/21426
-56-
target diseaselcondition or a specific stage of that diseaselcondition, tissue
or cells that have been or
are being subject to a treatment for that disease or condition, and/or a
tissue or cells taken from a
subject known to suffer from a different diseaselcondition ox stage thereof.
In the latter example, the
different disease/condition may be a disease or condition that is known to
affect a similar set or
subset of lipid metabolites, known to be influenced by similar drugs or
treatments, or is not related to
the target disease/condition with any currently identified correlation.
This invention provides methods for generating metabolite profiles,
particularly lipid
metabolite profiles, and assembling such profiles into consistent, comparable,
minable metabolomic
databases. The invention further provides methods for mining metabolomic
databases in order to
identify and understand metabolome-wide effects, for instance those effects
influenced by
pharmaceuticals, genes, toxins, diet, or the environment. Also provided are
databases, means for
accessing and mining such databases, and systems for such. It will be apparent
that the precise
details of the methods described may be varied or modified without departing
from the spirit of the
described invention. We claim all such modifications and variations that fall
within the scope and
spirit of the claims below.
